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Many of the most promising strategies for tissue engineering and regeneration aim to replicate
natural cellular microenvironments including matrix components, growth factors, and cellular
proteins as a means to guide the migration, proliferation, and differentiation of progenitor cells.
Combinations of growth factors synergistically enhance tissue regeneration, but typically require
sequential, rather than co-delivery from biomaterials for maximum efficacy. Polyelectrolyte
multilayer (PEM) coatings can deliver multiple factors without loss of activity; however,
sequential delivery has been limited due to interlayer diffusion of multiple factors that results in
co-delivery.
This dissertation examined the incorporation of a biomimetic calcium phosphate (bCaP)
layer into a poly-L-Lysine/poly-L-Glutamic acid PEM film (bCaP-PEM) to provide sequential
delivery of two different factors. The bCaP-PEM was uniformly deposited onto two-dimensional
(2-D), and three-dimensional (3-D) porous substrates. Measurements of MC3T3-E1
osteoprogenitor cell proliferation and viability over time were used to evaluate kinetics of active
biomolecule delivery and demonstrate that bCaP-PEM enables sequential delivery of a
proliferative factor (fibroblast growth factor -2 (FGF-2) followed by a cytotoxic factor
(antimycin A, AntiA) a few days later. Alterations to the PEM composition via increasing the
number of bilayers or using the D- enantiomer polyelectrolytes hindered delivery of the
proliferative factor. Increasing the bCaP layer thickness resulted in sustained delivery of the
embedded factor as compared to burst delivery. Accelerated cell-mediated delivery kinetics from
the bCaP-PEM coating was demonstrated in vitro using a murine macrophage cell line. Scanning
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electron microscopy revealed the bCaP-PEM coating could be uniformly applied to the 3-D,
commercially available bone graft substitute Healos®, (DePuy Synthes Spine, Raynham, MA).
Effects of sequential delivery of FGF-2, then bone morphogenetic protein 2 (BMP-2), from a
bCaP-PEM coated Healos® scaffold was evaluated in vivo in a mouse calvarial defect model.
This work resulted in the development of a novel, biomimetic coating capable of sequential
delivery of two factors. This technology has potential to be applied in multiple research
applications where a sequential delivery profile activated by cell degradation of the biomaterial
is desired.
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List of Figures
Figure 2.1 Schematic representation of interlayer diffusion of Factors 1 and 2 in a PEM only
coating (A), compared to prevention of interlayer diffusion of Factors 1 and 2 with the addition
of bCaP to the PEM coating (B). The theoretical co- and sequential delivery profiles from a PEM
only coating (C) and a bCaP-PEM coating (D) respectively.
Figure 2.2 Sandblasted disk coating procedure for diffusion studies. Step 1: Factor 2 (AntiA) is
adsorbed. Step 2A: disks are submerged in Solution A to deposit a thin layer of amorphous
calcium phosphate (CaP). Step 2B: disks are submerged in Solution B to deposit nanocrystalline
calcium phosphate, (bCaP). Step 3: 8-30 bilayers of PEM are applied by automated dip
procedure. Step 4: Factor 1 (FGF-2) is adsorbed.
Figure 2.3 Scanning electron microscopy images of the surface morphology and cross-section of
a sandblasted disk (A), and the sandblasted disks coated with: amorphous calcium phosphate
CaP (B), nanocrystalline calcium phosphate bCaP (C), nanocrystalline calcium phosphate and 30
bilayers of PEM (D), and 30 bilayers of PEM (E). B and E coating thickness was not measurable
via SEM. bCaP thickness = 5.8 + 1.8 μm (C). bCaP-PEM30 thickness = 16.3 + 2.2 μm (D).
Figure 2.4 EDS analysis of the bCaP deposited on the TCPsb before (A) and after PEM30
adsorption (B), revealed Ca/P atomic ratios of 1.95 + 0.12 and 1.52 + 0.50 respectively, not
statistically different from the hydroxyapatite powder (1.71 + 0.04) nor each other. The
composition of the bCaP coating was identified as poorly crystalline/nanocrystalline
hydroxyapatite by XRD (C). After PEM adsorption the bCaP became less crystalline (D).
Figure 2.5 AntiA dose response curve. The adsorbed AntiA IC50 was found to be 3.08 mM
(black arrow). The dose of AntiA selected to use for all studies was 40 mM (red arrow).
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Figure 2.6 Percent LIVE® stained area of MC3T3-Es cultured for 1 day on sandblasted disks
coated with normal AntiA (TCPsb-AntiA), AntiA after “PEM” processing, AntiA after “bCaP”
processing, and no AntiA (TCPsb). AntiA = 213 μg/disk. (**** p < 0.0001).
Figure 2.7 Day 1 percent cell death of MC3T3-E1s cultured on TCPsb coated with AntiA,
AntiA embedded under PEM8, and AntiA embedded under CaP-PEM8 relative to their AntiAfree controls (A). Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with
CaP-PEM8 (blue) and AntiA embedded under CaP-PEM8 (red) for days 1, 3, and 5 (B). AntiA =
213 μg/disk. (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
Figure 2.8 Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with CaPPEM30 (blue) and Anti embedded under CaP-PEM30 (red) for days 1, 3, 5, and 7. AntiA = 213
μg/disk. (* p < 0.05, ** p < 0.01).
Figure 2.9 Day 1 % LIVE® stained area of MC3T3-E1s cultured on AntiA with no coating
compared to its AntiA-free control, AntiA embedded under PEM30 compared to its AntiA-free
control, and AntiA embedded under bCaP-PEM30 compared to its AntiA-free control (A), (****
p value < 0.0001). The calculated day 1 % cell deaths of AntiA, AntiA-PEM30, and AntiAbCaP-PEM30 relative to their AntiA-free controls (B), (* p value < 0.05, *** p value < 0.001,
**** p value < 0.0001). Fluorescent images of LIVE® staining of MC3T3-E1s cultured on
TCPsb (C) vs. TCPsb coated with AntiA (D), PEM30 (E) vs. AntiA-PEM30 (F), and bCaPPEM30 (G) vs. AntiA-bCaP-PEM30 (H). Scale bar = 250 μm.
Figure 2.10 MC3T3-E1 FGF-2 dose response day 1 LIVE® staining. (* p < 0.05, ** p < 0.01,
**** p < 0.0001). The 150 ng FGF-2 dose was selected to use for all studies.
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Figure 2.11 Schematic representation of Factor 1 (A) and Factor 2 (B) location within the bCaPPEM30 coating. The theoretical immediate, and delayed delivery profiles of Factor 1 (C) and
Factor 2 (D) respectively.
Figure 2.12 LIVE® stained area of MC3T3-E1s cultured on bCaP-PEM30-FGF2 (blue) and
bCaP-PEM30 (green) for up to 5 days (A), (** p < 0.01, *** p < 0.001, **** p < 0.0001) (FGF2 = 150 ng/disk). Fluorescent images of day 1 LIVE® staining of MC3T3-E1s cultured on
TCPsb coated with bCaP-PEM30-FGF2 (B) and bCaP-PEM30 (C). Scale bar = 250 μm.
Figure 2.13 Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with bCaPPEM30 (green, -A/-F) and bCaP-PEM30-FGF2 (blue, -A/+F) at 4h (A), and day 1 (B), (** p <
0.01). Fluorescent images of LIVE® staining of MC3T3-E1s cultured on TCPsb coated with
bCaP-PEM30 and bCaP-PEM30-FGF2 after 4 h (C, D) and 1 day (E, F).
Figure 2.14 LIVE® stained area of MC3T3-E1s cultured on bCaP-PEM30 (green) and AntiAbCaP-PEM30 (red) for up to 5 days (A), (* p < 0.05, ** p < 0.01, *** p < 0.001) (AntiA = 213
μg/disk). Fluorescent images of day 3 LIVE® staining of MC3T3-E1s cultured on TCPsb coated
with bCaP-PEM30 (B) and AntiA-bCaP-PEM30 (C). Scale bar = 250 μm.
Figure 2.15 Percent LIVE® staining of MC3T3-E1s cultured in day 1- or day 3-release medium
collected from bCaP-PEM30-FGF-2 (-A/+F, blue) or AntiA-bCaP-PEM30-FGF-2 (+A/+F,
ornage) coated disks incubated at 37°C without cells, (FGF-2 = 150 ng/disk, AntiA = 213
μg/disk).
Figure 2.16 Day 1 LIVE® stained area of MC3T3-E1s cultured on the FGF-2 groups (+F)
compared to their FGF-2-free controls (-F) (FGF-2 = 150 ng/disk) (A), (*** p < 0.001, **** p <
0.0001). Percent LIVE® stained area of MC3T3-E1 cells cultured on bCaP-PEM30-FGF2 (blue)
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and AntiA-bCaP-PEM30-FGF2 (orange) over time (B), (**** p < 0.0001). Fluorescent images
of LIVE® staining of MC3T3-E1s cultured on bCaP-PEM30-FGF-2 (-A/+F), and AntiA-bCaPPEM30-FGF-2 (+A/+F), at time points 4 h, days 1-5 (C). Scale bar = 250 μm.
Figure 2.17 Schematic representation of “in and out” diffusion and exponential growth of
hydrophilic polyelectrolytes during layer-by-layer build up of the PEM film (A). Resulting
interlayer diffusion of multiple factors within the PEM layers (B) and theoretical co-delivery of
factors (C).
Figure 3.1 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP-PEM102-FGF2
(orange checker) as compared to cells cultured on bCaP-PEM102-FGF2 (blue checker) on days
1, 3, and 5 (A), (* p < 0.05). Percent LIVE® stained area of MC3T3-E1s cultured on the control
bCaP-PEM30-FGF2 as compared to cells on bCaP-PEM102-FGF2, (B), (*** p < 0.001).
Percent LIVE® stained area of MC3T3-E1s cultured on the control AntiA-bCaP-PEM30-FGF2
as compared to cells on AntiA-bCaP-PEM102-FGF2, (C), (* p < 0.05, ** p < 0.01). AntiA =
213 μg/disk, FGF-2 = 150 ng/disk.
Figure 3.2 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP-PEMD30-FGF2
(orange stripes) as compared to cells cultured on bCaP-PEMD30-FGF2 (blue stripes) on days 1,
3, and 5 (A), (**** p < 0.0001). Percent LIVE® stained area of MC3T3-E1s cultured on the
control bCaP-PEM30-FGF2 as compared to cells on bCaP-PEMD30-FGF2, (B), (* p < 0.05, **
p < 0.01). Percent LIVE® stained area of MC3T3-E1s cultured on the control AntiA-bCaPPEM30-FGF2 as compared to AntiA-bCaP-PEMD30-FGF2, (C), (* p < 0.05). AntiA = 213
μg/disk, FGF-2 = 150 ng/disk.
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Figure 3.3 Schematic representations of bCaP-PEM30 coatings made with bCaP prepared by 7 h
in Solution B (A), normal or 24 h in Solution B (B), and 48 h in Solution B (C).
Figure 3.4 Scanning electron microscopy images of the surface morphology and cross-section of
bCaP prepared by 7 h in Solution B (A), normal or 24 h in Solution B (B), and 48 h in Solution B
(C). bCaP(7) thickness = 1.8 + 0.7 μm, bCaP(24) thickness = 5.8 + 1.8 μm, and bCaP(48)
thickness = 24.0 + 2.4 μm.
Figure 3.5 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP(7)-PEM30FGF2, AntiA-bCaP(24)-PEM30-FGF2, and AntiA-bCaP(48)-PEM30-FGF2 on time points 4 h,
days 1-4 (A), (** p < 0.01). Fluorescent images of MC3T3-E1s cultured on AntiA-bCaP(7)PEM30-FGF2, AntiA-bCaP(24)-PEM30-FGF2, and AntiA-bCaP(48)-PEM30-FGF2 (B). AntiA
= 213 μg/disk, FGF-2 = 150 ng/disk.
Figure 3.6 Percent LIVE® stained area of MC3T3-E1s cultured on bCaP(24)-PEM30-FGF2 (A/+F) and AntiA-bCaP(24)-PEM30-FGF2 (+A/+F) (A) with corresponding fluorescent images
of cells (B), (**** p < 0.0001). (Note, this data is from Fig. 3.3 and is being shown for
reference). Percent LIVE® stained area of MC3T3-E1s cultured on bCaP(48)-PEM30-FGF2 (A/+F) and AntiA-bCaP(48)-PEM30-FGF2 (+A/+F) (C) with corresponding fluorescent images
of cells (D), (* p < 0.05, ** p < 0.01*** p < 0.001, **** p < 0.0001). (Note, data obtain for
Days 5, 6 and 7 were obtained from a separate experiment). Scale bar = 250 μm. AntiA = 213
μg/disk, FGF-2 = 150 ng/disk.
Figure 3.7 Theoretical delivery profiles of FGF-2 and AntiA from bCaP(24h)-PEM30
demonstrating burst delivery of AntiA (A) and bCaP(48h)-PEM30 demonstrating sustained
delivery of AntiA (B).
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Figure 3.8 Percent LIVE® stained area of RAW 264.7 s cultured on bCaP-PEM30-FGF2 (A/+F) (A), and AntiA-bCaP-PEM30-FGF2 (+A/+F) (B) at seeding densities of 7.9k or 30k
cells/cm2 (* p < 0.05, ** p < 0.01). Fluorescent images of the cells at 4 h of culture (C). Scale
bar = 250 μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk.
Figure 3.9 Percent LIVE® stained area of RAW 264.7 cells cultured on bCaP-PEM30-FGF2 (A/+F) and AntiA-bCaP-PEM30-FGF2 (+A/+F) seeded at 7.9k cells/cm2 (A), (* p < 0.05).
Fluorescent images of the cells at 4 h, 1 day, 2 days and 3 days of culture (B). Scale bar = 250
μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk.
Figure 3.10 Percent LIVE® stained area of RAW 264.7 cells cultured on bCaP-PEM30-FGF2 (A/+F) and AntiA-bCaP-PEM30-FGF2 (+A/+F) seeded at 30k cells/cm2 (A), (* p < 0.05, ** p <
0.01, *** p < 0.001). Fluorescent images of the cells at 4 h, 1, 2, and 3 days of culture (B). Scale
bar = 250 μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk.
Figure 3.11 Percent LIVE® stained area of RAW 264.7 cells seeded at 30k cells/cm2 on bCaPPEM30 (green, -A/+F), bCaP-PEM30-FGF2 (blue, -A/+F), AntiA-bCaP-PEM30 (red, +A/-F),
and AntiA-bCaP-PEM30-FGF2 (orange, +A/+F) at 4 h of culture, (A). Percent LIVE® stained
area of RAW 264.7s seeded at 30k cells/cm2 on AntiA-bCaP-PEM30 (red), and AntiA-bCaPPEM30-FGF2 (orange) at 4 h, and days 1-3, (B). (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p
< 0.0001). AntiA = 213 μg/disk, FGF-2 = 150 ng/disk.
Figure 3.12 The theoretical sequential delivery profile of FGF-2 and AntiA from bCaP-PEM30
cultured with osteoprogenitor cells (MC3T3-E1s at 40k cell/cm2) (A), as compared to the codelivery of factors from bCaP-PEM30 cultured with macrophages (RAW 264.7a at 30k
cells/cm2) (B).
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Figure 4.1 Schematic representation of BMP-2 only (A), and BMP-2 and FGF-2 (B) delivery
from Healos-bCaP-PEM. The theoretical single- (C), and sequential- (D) delivery profiles from
Healos-bCaP-PEM.
Figure 4.2 Schematic representation of the Healos-BMP2-CaP-PEM8-FGF2 procedure made
with only amorphous calcium phosphate (CaP) with no mixing, and 8 bilayers of PEM.
Figure 4.3 Schematic representation of the Healos-BMP2-bCaP-PEM30-FGF2 procedure made
with biomimetic, nanocrystalline, calcium phosphate (bCaP) with mixing, and 30 bilayers of
PEM.
Figure 4.4 Low magnification SEM images of Healos® (A) and Healos® coated with
amorphous CaP (B), (scale bar = 50 μm). High magnification SEM image of Healos® coated
with amorphous CaP (C), (scale bar = 10 μm).
Figure 4.5 SEM images of Healos® (A), Healos® coated with nanocrystallline bCaP(7) made
by 7 h in Solution B (B), and nanocrystalline bCaP(24) made by 24 h in Solution B (C), (scale
bar = 500 μm).
Figure 4.6 Low magnification SEM images of the outer and inner fibers of Healos® (A) and
Healos® coated with nanocrystalline bCaP(7) (B), (scale bar = 10 μm). High magnification SEM
image of the outer and inner fibers of Healos® coated with nanocrystalline bCaP(7) (C), (scale
bar = 1 μm).
Figure 4.7 SEM images of the outer (A) and inner fibers (B) of Healos® coated with
nanocrystalline bCaP(7) and 30 bilayers of PEM.
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Figure 4.8 4-week post-surgery x-rays (A, B), microCT 3-D reconstructions (C, D), and
microCT cross-sections (E, F) of calvaria implanted with Healos® coated with CaP-PEM8 (top
panel) and BMP2-CaP-PEM8 (bottom panel). BMP-2 dose = 0.5 μg. New bone formation is
circled in red.
Figure 4.9 Schematic representation of where within the defect FGF-2 effects are being
observed and quantified 1-week post-surgery (A). Fluorescent images of DAPI and EdU stained
cells showing increase in staining with the addition of 25 and 125 ng FGF-2 as compared to
BMP-2 alone (B). Quantified results showing 125 ng FGF-2 dose significantly increases number
of EdU+ cells on day 7 as compared to BMP-2 alone and 25 ng FGF-2 dose (C). (* p < 0.05, **
p < 0.01). (Healos® was coated with BMP2-CaP-PEM8 + FGF2).
Figure 4.10 4-week post-surgery microCT 3-D reconstructions (A, B), and microCT crosssections (C, D), of calvaria implanted with Healos® coated with BMP2-CaP-PEM8 (top panel)
and BMP2-CaP-PEM8-FGF2 (bottom panel). BMP-2 dose = 0.5 μg, FGF-2 dose = 125 ng. New
bone formation is circled in red and quantified in (E).
Figure 4.11 4-week post-surgery microCT 3-D reconstructions (top panel) and microCT crosssections (bottom panel) of calvaria implanted with Healos® coated with BMP2-CaP-PEM8 (A),
and BMP2-CaP-PEM8-FGF2 with an FGF-2 dose = 0.25 ng (B), 5 ng (C), and 100 ng (D).
BMP-2 dose = 0.5 μg. New bone formation is circled in red and quantified in (E). (* p < 0.05, **
p < 0.01).
Figure 4.12 3-week post-surgery microCT 3-D reconstructions (top panel) and microCT crosssections (bottom panel) of calvaria implanted with Healos® coated with bCaP(7)-PEM30 (A),
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BMP2-bCaP(7)-PEM8 (B), and BMP2-bCaP(7)-PEM8-FGF2 (C). BMP-2 dose = 2 μg, FGF-2
dose = 5 ng. New bone formation is circled in red and quantified in (D).
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List of Abbreviations
-A/-F

no AntiA, no FGF-2

-A/+F

no AntiA, FGF-2

+A/-F

AntiA, no FGF-2

+A/+F

AntiA and FGF-2

AntiA

antimycin A

bCaP

nanocrystalline calcium phosphate made with 24 h in Solution A

bCaP(24)

nanocrystalline calcium phosphate made with 24 h in Solution A

bCaP(48)

nanocrystalline calcium phosphate made with 48 h in Solution A

bCaP(7)

nanocrystalline calcium phosphate made with 7 h in Solution A

BMP-2

bone morphogenetic protein-2

BMP-5

bone morphogenetic protein-5

BMP-6

bone morphogenetic protein-6

BMP-7

bone morphogenetic protein-7

CaP

amorphous calcium phosphate

DAPI

2-(4-amidinophenyl)-1H -indole-6-carboxamidine

DS

dextran sulfate

ECM

extra cellular matrix

EDS

energy dispersive x-ray spectroscopy

EdU

5-ethynyl-2'-deoxyuridine

ELISA

enzyme-linked immunosorbent assay

Factor 1

PEM adsorbed factor to be delivered first

Factor 2

embedded factor to be delivered second
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FBS

fetal bovine serum

FDA

Food and Drug Administration

FGF-2

fibroblast growth factor-2

GCSF

granulocyte colony-stimulating factor

GDF-5

growth/differentiation factor-5

HA

hyluronan

IL6

interleukin 6

LBL

layer-by-layer

MC3T3E1

mouse osteoprogenitor cells

MCSF

macrophage colony-stimulating factor

MSCs

mesenchymal stem cells

OPG

osteoprotegerin

PAA

poly(acrylic acid)

PAH

poly(allylamine hydrochloride)

PDGF

platelet derived growth factor

PDGlut

poly-D-Glutamic acid

PDLys

poly-D-Lysine

PEG

polyethylene glycol

PEM

polyelectrolyte multilayer

PEM102

polyelectrolyte multilayer with 102 bilayers

PEM30

polyelectrolyte multilayer with 30 bilayers
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Chapter 1
Introduction and Specific Aims
1.1 Introduction
We have entered an era of regenerative medicine resulting in new biomimetic coatings and
implantable devices focused on not just repairing the injured or diseased tissue, but on
stimulating the body’s natural tissue regeneration. As a result, new multi-component biomaterial
drug delivery systems are being developed to initiate multiple, critical aspects of the natural
biological tissue regeneration process, including: infection control [1], as well as recruitment and
migration [2], and proliferation and differentiation [3] of progenitor cells. These processes are
generally governed by the timely release and exposure to multiple growth factors [4, 5].
Therefore rather than being limited to the delivery of a single growth factor, biomaterial systems
are needed to control the release of multiple therapeutic agents at optimized physiological doses,
ideally with specific spatiotemporal patterns [6]. This dissertation is focused on the development
of a novel, biomimetic, multifactor, sequential delivery system capable of being applied to twodimensional or three-dimensional substrates; in addition, the delivery system is used to
investigate the potential biological benefit of sequential delivery of growth factors to stimulate in
vivo osteogenesis.
1.1.1 Growth Factors Used in Clinical Trials and Commercial Products
There are a number of growth factors already being clinically investigated to stimulate natural
tissue regeneration. These include vascular endothelial growth factor (VEGF, clinical trials) [715], fibroblast growth factor-2 (FGF-2, clinical trials) [15-18], bone morphogenetic protein-2
(BMP-2, INFUSE Bone Graft, Medtronic, FDA approved) [19, 20], bone morphogenetic protein-
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7 (BMP-7, OP-1 Putty, Stryker, FDA approved) [21, 22], and platelet-derived growth factor
(PDGF-BB, GEM 21S, Osteohealth, FDA approved) [23, 24]. VEGF and FGF-2 have been
primarily focused on the treatment of cardiovascular diseases, while BMP-2 and BMP-7 have
been focused on bone fracture and defect repair, and PDGF-BB was created to enhance
periodontal regeneration. To date, no clinical trials in the USA have been conducted on the use
of FGF-2 on bone fracture repair, however clinical trials in Japan have shown that local
administration of FGF-2 accelerates healing of tibial shaft fractures [25], and stimulates
periodontal regeneration [26].
The successful use of growth factors clinically has been very limited. For example, when
administered intravenously, VEGF has a half-life of only 30 min [13], resulting in the need for
excessive dosing and injections [14, 15]. Excessive VEGF should be avoided because it can lead
to pathological vessel formation at non-target sites [27]. BMP-2 delivered via a collagen sponge
(INFUSE Bone Graft, Medtronic, FDA approved) significantly enhances bone formation and
successful spinal fusion [28]; however its use has been limited due to complications with the
required high dose of BMP-2 necessary for adequate bone formation. It only takes nanogram
quantities of BMP-2 per gram bone matrix to trigger the bone repair cascade, however
microgram quantities of BMP-2 per gram of the matrix material are required to produce adequate
bone formation [4, 29].

These complications include severe inflammation, ectopic bone

formation, osteolysis, seroma formation, and possible increase in the risk of malignancy, [19,
30]. These problems stem from the collagen sponge’s inability to contain the supraphysiologic
dose of BMP-2 in the local tissue environment.
Healos® is a commercially available bone graft substitute made of type I collagen fibers
with a hydroxyapatite coating (DePuy Synthes Spine, Raynham, MA). Healos® has been
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investigated for the delivery of human growth/differentiation factor-5 (GDF-5) [31, 32], and
BMP-2 [33] to aide in bone regeneration. Again the success of these approaches has been
limited. Gohil et al. discovered that delivery of BMP-2 from Healos® was not confined to the
site of BMP-2 implantation and significant bone formation was observed in the neighboring
defect site [33].
It is postulated that the reason the clinical use of growth factors and their combination
with commercial scaffolding materials have unwanted side effects is because the delivery
approaches employed lack any control over release.

These factors were intravenously

administered [14-16] or were adsorbed as a bolus dose of growth factor to a scaffolding material
[19-22]; because these methods lack controlled release, supraphysiologic, excessive, doses need
to be used to obtain the desired therapeutic effect. This is because a significant portion of the
administered growth factor will diffuse away from the implantation site and be degraded via
denaturation, oxidation or proteolysis [34, 35]. If the growth factor manages to remain active, the
diffusion can lead to off-target, unwanted side effects [19, 27, 30, 33]. These unfavorable
outcomes emphasize the need to develop a way to not only reduce the concentration of growth
factor necessary to obtain a therapeutic effect, but to also develop biomaterials capable of
controlling the release and delivery of these growth factors.
1.1.2 Biology of Bone Repair
Bone repair and regeneration involves the combination of cells, bioactive factors and
extracellular matrix to stimulate the proliferation, differentiation and migration of
osteoprogenitor cells [5, 36, 37]. Fracture healing can occur in two ways, primary (direct)
fracture healing, or secondary (indirect) fracture healing. Primary fracture healing requires rigid
fixation and leads to the regeneration of bone structure without remodeling steps. The majority
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of bones heal through secondary (indirect) fracture healing which consists of both endochondral
and intramembranous bone healing [38]. Secondary fracture healing involves the following
stages: hematoma formation, inflammation, callus formation, revascularization, mineralization
and resorption of the callus, and bone remodeling [39]. After fracture, the hematoma will form
within hours and begin the acute inflammatory stage that typically lasts around 3 days. This step
is critical to bone healing because the hematoma initiates the signaling cascade that leads to
successful bone formation [39, 40]. Inflammatory cells, including monocytes, will migrate into
the extra cellular matrix (ECM) of the hematoma from the ruptured blood vessels and bone
marrow cavity. Mesenchymal stem cells (MSCs) will be recruited to the fracture site when cells
within the hematoma release signaling molecules such as interleukin 6 (IL6), tumor necrosis
factor alpha (TNFα), granulocyte colony-stimulating factor (GCSF), stromal cell-derived factor1 (SDF 1), and macrophage colony-stimulating factor (MCSF) [41]. The source of MSCs is an
area of active investigation, however it is believed that they derive from the bone marrow and
periosteum, and possibly bone lining cells [42].
During the first few days of fracture healing granulation tissue is formed within the defect
where cartilaginous tissue will then form (soft callus) around days 7-10 and serve to aid in
fracture stabilization [43] (endochondral ossification); simultaneously, an intramembranous
ossification response occurs at the proximal and distal ends of the fracture adjacent to the
periosteum, generating a hard callus [38]. During this time chondrocytes will undergo
hypertrophy and the cartilaginous callus will calcify. Concurrently, blood vessels will penetrate
the chondrogenic tissue, bringing with them mesenchymal progenitors that initiate cartilage
replacement with woven bone [38]. During this time, collagen type I and II matrix production
increases, and expression of members of the transforming growth factor-β superfamily (TGF-β2,
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-β3, GDF-5, BMP-2, -5, and -6) which are involved in cell proliferation and differentiation, will
elevate [44, 45]. Vascular endothelial growth factor (VEGF), known to be highly expressed in
hypertrophic chondrocytes, is considered a key regulator in the transformation of the
cartilaginous matrix into vascularized osseous tissue [46]. The osseous matrix, or hard callus,
will then gradually be replaced with woven bone via osteoclast resorption of the hard callus.
This stage of fracture repair is associated with expression of collagen type I, osteocalcin, and
alkaline phosphatase [47], and relies on key regulators of bone homeostasis such as receptor
activator of nuclear factor kappa-β ligand (RANKL), receptor activator of nuclear factor kappa-β
(RANK) and osteoprotegerin (OPG) [48, 49]. During the remodeling phase, woven bone will be
resorbed by osteoclasts and replaced by lamellar bone via osteoblasts, leading to the mechanical
and biological restoration of bone function [38].
In the present studies, a critical-sized calvarial defect mouse model was selected for the
in vivo experiments, which also heals through secondary (indirect) bone formation. Contrary to
callus formation and subsequent endochondral ossification, which is the main mechanism of
secondary (in direct) fracture healing described previously, calvarial defects repair and
regenerate in a slightly different way with their main mechanism of bone healing being
intramembranous ossification. Intramembranous ossification is a more direct method of bone
formation that skips the cartilaginous steps associated with endochondral ossification. During
intramembranous ossification, inflammatory cells and MSCs will first be recruited to the defect
site. The MSCs will replicate and condense into compact nodules committing themselves as
osteoprogenitor cells. These cells will differentiate into osteoblasts and secrete a collagenproteoglycan matrix that is able to bind calcium salts [50], and are associated with the expression
of type 1 collagen, bone sialoprotein and osteocalcin [51]. Through this binding, the matrix
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becomes calcified with the enzyme alkaline phosphatase playing a key role [52].

As

calcification proceeds bony spicules will radiate out from the region where ossification began.
During this process some osteoblasts will become trapped within the bony pockets and will then
differentiate into osteocytes or mature bone cells [52]. Over time, the defect will be filled with
spongy bone that will continually be remodeled through the combined action of osteoblasts and
osteoclasts. At this point new bone formation is slowed and the compact MSCs surrounding the
area of new bone formation will form the periosteum [50]. The mechanism of intramembranous
ossification is primarily controlled through fibroblast growth factors (FGFs), with FGF-2 and
FGF-18 being considered most important for calvarial regeneration [51], bone morphogenetic
proteins (BMPs), and the transcriptional factor core-binding factor alpha (1) (Cbfa1). Cbfa1 is
considered to play a critical role during BMP-induced osteoblastic differentiation [53]. In
addition it has been shown that BMPs act in concert with FGFs to control calvarial growth,
development, and regeneration [54] and will be further discussed in the following section.
Considering the important roles of osteoprogenitors and osteoblasts on bone regeneration,
a mouse osteoprogenitor/pre-osteoblast cell line, MC3T3-E1s, was selected for our in vitro
assays to screen the effectiveness of the biomaterial to provide sequential, multifactor, cellmediated delivery. In addition to the osteoprogenitors, monocytes and osteoclasts are two other
cell types that play a vital role in bone regeneration and fracture healing. As new bone matrix is
deposited by osteoblasts on the outer surface of new bone, subsequent resorption of bone matrix
on the inner surface is accomplished via osteoclasts. Osteoclasts are multinucleated cells that are
derived from the same precursors as monocytes. These monocytes enter the healing defect site
through the blood vessels and will differentiate into osteoclasts in the presence of RANKL,
which is secreted by the osteoprogenitor cells already present in the defect [55]. The osteoclasts
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are capable of dissolving both the inorganic and the protein portions of the bone matrix. They
accomplish this by extending their cellular processes into the matrix and pumping out hydrogen
ions into the surrounding material, thereby producing an acidic environment that can dissociate
the mineralized matrix [50]. The combined action of osteoblasts and osteoclasts must be tightly
regulated for bone fracture healing and normal bone maintenance, therefore the cells and their
precursors can act on each other. In addition to secreting RANKL and colony-stimulating
factor both promoting osteoclast differentiation [56], osteoprogenitors can also secrete
osteoprotegerin, deterring the differentiation of osteoclasts [55]. FGF-2 (provided from
macrophages, MSCs and osteoblasts [36]) can increase the formation of osteoclast-like cells [57]
and activate mature osteoclasts [58]. The actions and effects of all of these cell types are
important to consider when developing a biomaterial to enhance bone regeneration, therefore a
mouse monocyte cell line, RAW 264.7s, was selected to also screen the effectiveness of the
biomaterial to provide sequential, multifactor, cell-mediated delivery in vitro.
1.1.3 Growth Factors Involved in Bone Repair and Regeneration
One focus of the research conducted in this dissertation was to use a biomaterial to
deliver multiple growth factors to stimulate the production of osteoblasts to produce new
mineralized bone tissue. This involves first the recruitment to, and commitment of mesenchymal
stem cells to the osteoblast lineage making them osteoprogenitors, followed by the proliferation
of the osteoprogenitors, and then differentiation of the osteoprogenitors into functioning
osteoblasts [59]. There are a number of growth factors involved in bone regeneration, but the
major factor families involved with proliferation and differentiation of osteoprogenitors are
fibroblast growth factors, transforming growth factor-βs, and bone morphogenetic proteins [36].
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Bone morphogenetic proteins (BMPs) are the main growth factors responsible for the
differentiation of osteoprogenitor cells into functioning osteoblasts [36]. BMP-2, -4, and -7 have
all been investigated for bone regeneration, however, it has been suggested that BMP-2 may be
more osteoinductive compared to other BMPs [60]. BMP-2’s use clinically was the result of its
extensive investigation in vivo in a variety of animal models; BMP-2 has been shown to
stimulate bone regeneration in rats [61-63], rabbits [64, 65], dogs [66, 67], sheep [68, 69], and
monkeys [65]. Because of its proven effectiveness at regenerating bone in vivo, and it use
clinically, BMP-2 was selected as one of the growth factors to be delivered in the present studies.
There are twenty-two members to the fibroblast growth factor family [36], however
fibroblast growth factor-2 (FGF-2) has been studied most for use in bone fracture healing. This
is because FGF-2 is known stimulator of osteoprogenitor proliferation [70] and plays an
important role in maintaining bone mass [71]. FGF-2 has been shown to accelerate fracture
healing via increasing callus size, mineral content, and mechanical strength of the healing defect
site [72-75]. The Fgf2 gene is expressed during all stages of the fracture repair process [76], and
its receptor (Fgfr2) is specifically expressed at sites of intramembranous ossification in
differentiating osteoblasts [77]. Besides its clear involvement in bone fracture healing, FGF-2
was selected for use in the present studies because of its synergistic effects when used with
BMP-2. FGF-2 has been demonstrated to increase the BMP-2 sensitivity of osteoprogenitor cells
[78, 79] via up-regulating BMP-2 levels and BMP-2 receptor expression [80, 81]. Recently, low
concentrations of BMP-2 were shown to enhance calvarial defect repair in mice overexpressing
FGF-2 in osteoprogenitor cells [82], suggesting FGF-2 can augment BMP-2-induced bone repair
[83]. These findings lead to the hypothesis that the combined use of FGF-2 and BMP-2 could
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decrease the supraphysiologic dose of BMP-2 necessary to stimulate bone formation, thereby
decreasing the unwanted, off-target side effects that are associated with BMP-2’s clinical use.
1.1.4 Optimizing FGF-2 and BMP-2 for Bone Healing
There have been several studies investigating the combined use of FGF-2 and BMP-2 on in vitro
and in vivo osteogenesis [84-101].

At first glance, the results of these studies have been

somewhat contradictory. For the most part, the combined use of FGF-2 and BMP-2 has been
reported as stimulatory and synergistic.

However there are many examples where their

combined use has been reported as inhibitory on osteogenesis [84, 86, 93, 95, 96, 100, 102].
There are many factors to consider when combining growth factors. For example, Charles et al.
observed that the co-delivery of FGF-2 and BMP-2 in a mouse calvarial defect model was not
stimulatory on in vivo osteogenesis over BMP-2 alone in young adult mice; however, the codelivery of both factors did in fact aid in new bone formation when tested in old mice [84]. There
have also been examples where the combined use of FGF-2 and BMP-2 resulted in both
stimulatory and inhibitory results [86, 93, 96]. In these studies it was found when combining
high doses of FGF-2 (μg quantities) with BMP-2 it was inhibitory, where as low doses of FGF-2
(ng quantities) with BMP-2 tended to be stimulatory. The relative dosing of BMP-2 to FGF-2
also seems to be important. Wang et al. reported that ratios 8:1, 4:1, and 2:1 (BMP-2: FGF-2)
were all stimulatory for in vitro and in vivo osteogenesis, however 2:1 produced the best
outcomes [103]. For the examples where both stimulatory and inhibitory results were reported,
ratios of 5:1 to 500:1 stimulated osteogenesis, where ratios of 1:1 and 1:25 were inhibitory [86,
93, 96], suggesting the FGF-2 dose should be low compared to the BMP-2.
Besides dosing and taking into account the osteogenic potential of the model/cells being
used (young vs. old), sequence of delivery is crucial to the success of the combined use of FGF-2
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and BMP-2. The best chance of success when using multiple growth factors is to mimic the
natural tissue regeneration process. Growth factors have different effects on tissue regeneration
depending on the developmental stage of the healing process they are present during. As
previously mentioned FGF-2 has proliferative effects on osteoprogenitors (early), and BMP-2 is
the key factor involved in osteoprogenitor differentiation (late). All of the inhibitory examples
previously mentioned were co-delivery [86, 93, 95, 96, 100, 102]. In vitro studies have
demonstrated that spiking first FGF-2 in cell culture medium, and then BMP-2 can increase
osteogenesis over co-delivery of both factors and/or single factor delivery [85, 88, 90, 91]. BMP2 delivered too early, or before FGF-2 has been shown to be inhibitory [89, 104]. These results
stress the need for new biomaterials to biomimetically deliver multiple growth factors in a
sequential manner to maximize their stimulatory effects.
1.1.5 Material Approaches for Growth Factor Delivery for Bone Regeneration
A successful growth factor delivery biomaterial will maintain therapeutic concentrations of
growth factor at the application site in a spatiotemporal pattern that mimics natural bone
regeneration. There are two main approaches for the delivery of growth factors from
biomaterials: 1) physical encapsulation of the growth factors in the delivery system, and 2)
chemical immobilization of the growth factors to the matrix/substrate. Physical encapsulation
relies on both the diffusion of the growth factor out of the material and degradation rate of the
material; chemical immobilization relies on chemical binding or affinity interactions between the
growth factor and the substrate [4, 5, 27]. There are pros and cons to each approach.
Chemical immobilization incorporates a variety of techniques to conjugate growth factors
directly to a scaffold or biomaterial. The simplest approach to delivering growth factors for bone
regeneration involves the adsorption of growth factors directly to a scaffold through non-
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covalent binding (surface adsorption, ionic complexation) [5, 105]. As previously mentioned,
surface adsorption approaches can result in rapid release of the growth factor and an inability to
contain the growth factor to the local tissue environment due to diffusion away from the implant
site [19, 30, 33]. On the contrary, when growth factors have a high affinity for the biomaterial,
release tends to be limited.

For example, BMP-2 has a high affinity for calcium

phosphate/hydroxyapatite type materials; in vitro release from these types of materials is usually
very low (10-30%) [84, 106-108]. However, this is not necessarily undesirable; the high affinity
to the scaffold material means the growth factor is readily available for cells to come into contact
with the scaffold, providing a highly localized delivery [27, 109, 110]. Covalently immobilizing
the growth factor to the scaffold can provide more prolonged release. This is because if the
growth factor remains active after covalently tethering it to the biomaterial or scaffold then it
will still activate the growth factor receptors on the cells, but it will be more slowly degraded and
internalized [27]. A drawback to this approach is that covalently immobilizing the protein to the
scaffold can result in conformation changes to the growth factor’s functional groups, resulting in
its inactivation [111].
Physical encapsulation approaches include use of polymeric vehicles, hydrogels, and
particles for delivery of growth factors. Polymers are advantageous for growth factor delivery
because depending on the method of growth factor incorporation, release rate can be controlled
by processes such as diffusion, charge interactions, erosion and degradation of the polymer,
swelling of the polymer, or dissolution [112, 113]. Disadvantages to polymer delivery include
denaturing and deactivation of proteins resulting from the encapsulation processes that usually
require the use of harsh solvents, cross-linking agents and high temperatures [4].
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A way to physically entrap growth factors but to avoid high temperatures and harsh
solvents is to utilize hydrogels [114]. Hydrogels are highly hydrated networks of cross-linked
polymer chains formed from natural (collagen and hyaluronic acid), synthetic (polyethylene
glycol) or semi-synthetic polymer backbones [115]. Growth factor delivery from hydrogels
depends on the physiochemical properties of the polymer structure and the bioactive factor, and
control over the growth factor delivery is usually dependent on the type and density of crosslinkers [5]. A variety of materials have been used to produce hydrogels for single osteoinductive
factor delivery including alginate [116, 117], gelatin [118, 119], fibrin [120], hyaluronic acid
[79], and polyethylene glycol (PEG) [121]. Increasing the amount of cross-linking will decrease
the degradation of the hydrogel and slow the release rate of the incorporated factor.

For

example, in vitro and in vivo BMP-2 release from hydrogels was found to directly correlate to
the density of cross-linkers and water content within the scaffold (cross-linkers released BMP-2
through hydrolysis) [120, 122, 123]. A con to the use of hydrogels is that growth factor release
is typically dependent on cross-linking; increasing the extent of cross-linking reduces the cytocompatibility of the hydrogel and can deactivate incorporated proteins [5]. Hydrogels are also
limited to only being able to provide one rate of release at a time; therefore their use for
multifactor delivery is limited to co-delivery. Simmons et al. showed they could vary the
degradation rate of their alginate hydrogel, therefore they could vary the release of rate of their
incorporated factors either individually, or in combination, but they could not sequentially
deliver the growth factors in combination [124].
A way to vary the release rates of multiple growth factors from a hydrogel is to make a
composite material via the addition of particles to the hydrogel and/or scaffold with each
component containing a different factor.

Encapsulation of growth factor via a micro- or
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nanoparticle [125-129], or liposome [130] is a strategy commonly employed to provide sustained
release and retain growth factor activity. Encapsulating a growth factor into a particle, then
incorporating those particles into a hydrogel that also has an entrapped growth factor, is way to
achieve two distinct release profiles for a multifactor delivery system [131, 132]. Sequential
delivery from a system such as this is still difficult to achieve; this is because release of the
particles from the hydrogel and release of the entrapped growth factor from the hydrogel are
occurring simultaneously, but at different rates. For true, sequential delivery, delayed release or
delivery for at least one growth factor must be achievable through the biomaterial.
1.1.6 Polyelectrolyte Multilayer Films
A popular biomaterial strategy for multifactor delivery is the use of polyelectrolyte multilayer
(PEM) films. PEM is a layer-by-layer (LBL) build-up of oppositely charged polyelectrolytes, a
polyanion (-) and polycation (+), to form a thin film. PEM films were first introduced 20 years
ago by Moehwald, Decher, and Lvov [133, 134] in attempts to produce thin films that could be
used in biomedical applications to make surfaces more functionalized and render them more
biomimetic. In the first 10 years of their introduction PEM films were only used in proof-ofconcept studies producing films containing small charged species such as biological molecules
(polypeptides, polysaccharides, DNA, proteins, viruses) and various kinds of nanoparticles
[135]. It was not until 2001 when the first study with a PEM film was used to observe the
behavior of cells interacting with the coating [136]. In the past ten years, possibilities for the
spatiotemporal control over cell growth and the use PEM films in vivo has been investigated
[137].
As mentioned, PEM films are formed by alternately depositing oppositely charged
polyelectrolyte that self-assemble and self-organize on a substrate’s surface. For the most part
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the LBL build up of PEM films relies on the electrostatic interactions between the
polyelectrolytes, however non-electrostatic interactions, including hydrophobicity [138],
hydrogen bonds [139], Van der Waals forces, halogen interactions [140], and covalent bonding
[141] can influence the architecture of the film. The most common PEM application method is to
dip coat the substrate [137], i.e. dip the substrate into the polyanion solution, rinse, dip into the
polycation solution, rinse, etc.; however, PEM can also be applied via spray coating [142] or spin
coating [143]. Dip coating requires rinse steps between polyelectrolyte application because the
excess solution needs to be completely removed before application of the next polyelectrolyte
otherwise the PEM will precipitate in solution rather than depositing onto the substrate as the
next layer; spray coating removes the need of excess solution, therefore rinse steps can be
skipped and accelerate the PEM application process [142].
The growth of PEM films via LBL build up can be linear or exponential depending upon
the polyelectrolytes used in the film. The original development of PEM films showed linear
growth of film thickness with increasing number of layers deposited, and this growth is typical
with use of polyelectrolytes such as poly(styrene sulfonate) (PSS) and poly(allylamine
hydrochloride) (PAH) [144].

More recently exponential growth of film thickness with

increasing number of layers deposited has been described with use of polyelectrolytes such as
poly-L-Lysine (PLLys), alginate, and hyluronan (HA) [145, 146]. PEM films made up of
polyamino acids and polysaccharides tend to result in exponential film growth [137], however
even some synthetic polyelectrolytes such as polyacrylic acid (PAA) will also grow in this
manner [147]. The use of natural polyelectrolytes, such as polyamino acids and polysaccharides,
is desirable because these materials are biomimetic and have better biocompatibility in vivo.
Exponential growth of PEM coatings is a result of “in and out” diffusion of the polyelectrolytes

14

Emily Elizabeth Jacobs – University of Connecticut, 2016

[146]. As the film is exposed to a polyanion (-) solution, the polycation (+) within the film will
diffuse to the surface allowing for more binding sites for the polyanion. Vice versa will occur
during the next step when the polycation solution is being applied. This results in thicker and
thicker layers of PEM being applied with each subsequent step. In addition to the type of
polyelectrolytes used, molecular weights of the polyelectrolytes can influence the “in and out”
diffusion occurring within the film, thus influencing the exponential growth of the PEM film.
Increasing the molecular weight of both synthetic polyelectrolytes (PAA in PAH/PAA film)
[148] and natural polyelectrolytes (PLLys in PLLys/HA film) [149] restrained the ability of these
polyelectrolytes to diffuse within the film.
The inter-diffusion of polyelectrolytes is now considered a “dominant” process involved
with the use of PEM films, and this phenomenon is critical for understanding loading and release
kinetics of bioactive molecules deposited into the films [137]. One of the most attractive features
of PEM systems in their ability to retain the bioactivity of molecules incorporated into the films
and to act as a reservoir for delivery of small molecules [150]. The layer-by-layer assembly
technique allows for easy control over the order of which small molecules are incorporated into
the film, and because the molecules are directly integrated in the architecture of the film via
electrostatic interactions and do not require covalent bonding [151, 152], their secondary
structures remain close to their native form and this retains their biological activity [111].
Because the incorporated molecules rely on electrostatic interactions within the PEM films, they
too will diffuse throughout the PEM film during exponential film growth. Vodouhe et al.
showed that a fluorescently labeled molecule purposely adsorbed within one location of a
PLLys/HA film, ultimately could be observed throughout the entire thickness of the film [153].
For single factor delivery from PEM films, this can be considered a desirable effect of the film
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growth because the PEM now serves as a reservoir for the molecule. In the same study, it was
shown that increasing the film thickness increased the amount of drug that could be loaded into
the PLLys/HA film [153].
Issues with the exponential growth of PEM films become a problem when multiple small
molecules are being incorporated into the film and the sequence of their release is trying to be
controlled. Multiple factors can be adsorbed into PEM films at specific locations within the films
but the “in and out” diffusion that occurs during the build up of the film will result in a blended
architecture lacking controlled order, therefore resulting in uncontrolled delivery [154]. To
prevent interlayer diffusion of molecules through exponentially growing PEM films, “blocking
layers” can be added to act as barriers within the films. These can include cross-linking layers
within the film [147], using slowly degradable polymers such as poly(lactic-co-glycolic acid)
within the film [155], or introducing a third component into the PEM film that acts as a physical
barrier [156, 157]. The only way to achieve multifactor, sequential delivery from PEM films
made with exponentially growing, biocompatible, polyelectrolytes is to prevent interlayer
diffusion within the film.
The use of PEM films by themselves has been shown to aid in the biocompatibility of
titanium implants interacting with osteoblast cells [158, 159]. In addition, individual and
combinations of bioactive growth factors have been successfully delivered from PEM systems,
including osteogenic factors such as FGF-2, TGFβ1, and BMP-2, and retained their bioactivity
[160-167]. It was therefore decided that a PEM system could be developed for delivery of FGF-2
and BMP-2 in hopes to stimulate osteogenesis for enhanced bone regeneration.
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1.2 Specific Aims
The goal of the research is to develop a biomaterial capable of sequential delivery of multiple,
biologically active factors. The long-term goal is to develop a material that can sequentially
deliver low dose FGF-2 and BMP-2 and be applied to a commercially available bone graft
substitutes to enhance in vivo osteogenesis and potentially overcome clinical complications with
high dose BMP-2. The successful biomaterial will deliver FGF-2 during the first few days of
fracture

healing,

then

deliver

BMP-2;

inflammation

and

osteoprogenitor

recruitment/proliferation need to subside before delivering the differentiation agent from the
biomaterial. The novelty of this work is the incorporation of a biomimetic calcium phosphate
(bCaP) barrier layer into poly-L-lysine/poly-L-glutamic acid PEM design to prevent interlayer
diffusion of growth factors resulting in a sequential, multifactor, bioactive delivery system that
can be applied to two-dimensional (2-D) and three-dimensional (3-D) substrates. It is
hypothesized that: If bCaP barrier layer can prevent diffusion of multiple factors within a
PEM coating, then sequential delivery of factors can be achieved from a bCaP-PEM coated
biomaterial. This objective will be completed with the following specific aims:
Aim 1: Develop a biomimetic calcium phosphate-polyelectrolyte (bCaP-PEM) coating for
sequential, multifactor delivery in vitro. Hypothesis: If bCaP barrier layer can prevent
diffusion of multiple factors within a PEM coating, then sequential delivery of factors can be
achieved from bCaP-PEM. Simulated body fluid (SBF) methods have been developed to form
bCaP coatings on tissue culture plastic disks [168] that were utilized to achieve this aim. bCaP
coatings are expected to provide a biocompatible barrier layer within the PEM design. Scanning
electron microscopy (SEM), energy-dispersive x-ray spectroscopy, and x-ray diffraction were
used to assess the morphology, composition, and structure the bCaP layer before and after PEM
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application. To demonstrate sequential delivery a combination of a proliferative factor (FGF-2)
and a cytotoxic factor (antimycin A) with opposing effects on MC3T3-E1 mouse calvarial
osteoprogenitor cells were adsorbed into the coating to clearly demonstrate when cells were
accessing the incorporated factors. Proliferative and cytotoxic effects were quantified using
LIVE® staining (Invitrogen Life Technologies, Grand Island, NY) and ImageJ analysis. Release
studies were conducted to determine if factors were released from the bCaP-PEM coating via
diffusion.
Aim 2: Demonstrate in vitro, cell-mediated delivery kinetics of multiple factors from the
bCaP-PEM coating can be tuned by altering the structure/composition of the coating or
changing the cell type used with the coating. Hypothesis: If delivery of the embedded factor is
a function of coating thickness, then delivery kinetics of that factor can be further delayed by
thickening the bCaP layer within the coating. Tunable delivery kinetics were assessed using the
same MC3T3-E1 proliferation studies on coatings prepared with alterations made to the bCaP
layer by increasing or decreasing time in the SBF solutions resulting in a thinner or thicker layer.
Alternations to the PEM portion of the coating were also investigated to tune delivery kinetics of
the incorporated factors via increasing the number of PEM bilayers and/or the use of Denantiomers polyelectrolytes. Additionally, delivery kinetics were assessed using RAW 264.7
mouse macrophage cells to determine how cell type can change the cell-mediated
degradation/delivery of the coating.
Aim 3: Characterize bCaP-PEM coating applied to 3-D scaffolds, and determine the effects
of sequential delivery of FGF-2 and BMP-2 on in vivo osteogenesis. Hypothesis: If sequential
delivery of low dose FGF-2 and BMP-2 is a beneficial method of stimulating bone formation,
then sequential delivery vs. co- or single factor delivery will result in increased in vivo
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osteogenesis. The Kuhn lab previously demonstrated that sequential delivery of low dose FGF-2,
followed by BMP-2 enhanced in vitro osteogenesis over co- or single factor delivery [88],
therefore it is expected that this delivery sequence from bCaP-PEM would stimulate in vivo
osteogenesis. SEM was used to access surface morphology and coating application of the bCaPPEM coating applied to a commercially available bone graft substitute scaffold. Sequential
delivery of first FGF-2, then BMP-2 from bCaP-PEM applied to a scaffold was evaluated using
an in vivo mouse calvarial defect model. New bone formation 3-4 weeks post-surgery was
assessed using x-ray and microCT. Sequential delivery was compared to BMP-2 only delivery
and the scaffold with no coating.
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Chapter 2
Biomimetic Calcium Phosphate/Polyelectrolyte Multilayer Coatings for Sequential Delivery of
Multiple Biological Agents
2.1 Introduction
New multi-component biomaterial drug delivery systems are being developed to initiate
multiple, critical aspects of the natural biological tissue regeneration process, including: infection
control [1], as well as recruitment and migration [2] and proliferation and differentiation [3] of
progenitor cells. These processes are governed in the body by the timely release and exposure to
multiple growth factors [27, 36]. Therefore rather than being limited to the delivery of a single
growth factor, biomaterial systems are needed to control the release of multiple therapeutic
agents at optimized physiological doses, ideally with specific spatiotemporal patterns [6].
Several different types of delivery systems for multiple growth factors have been
developed as potential therapeutics for wound healing/infection, bone, cartilage, muscle, teeth
and cancer, and have shown some efficacy both in vitro [1, 88, 131, 169, 170], and in vivo [101,
167, 171]; however, their success has been limited. The drawback of these systems, including
microspheres [1], nanoparticles [169], and hydrogels [131, 171] is their co-delivery of factors.
Growth factors have different effects on natural tissue regeneration depending on the
developmental stage of the healing process they are present during; therefore, sequence of
delivery is important to optimize growth factor activity and healing.
A popular biomaterial strategy for multifactor delivery of growth factors or other
biologically active molecules incorporates the use of polyelectrolyte multilayer (PEM) films.
PEM is a layer-by-layer (LBL) build-up of oppositely charged polyelectrolytes, a polyanion (-)
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and polycation (+). These PEM films offer a means of temporal regulation of bioactive factors
without loss of their biological activity [150]. In addition, the release kinetics of factors from
PEM can be adjusted by alternating number of layers within the film, changing the type of
polyelectrolytes [154], or introducing a third component/barrier layer [156, 157]. PEM can also
be applied to two dimensional or three-dimensional porous, intricate substrates and scaffolds as
thin films making PEM applications versatile. The layer-by-layer PEM delivery system is now
widely being used for co-delivery of multiple factors; however, controlled, sequential delivery
from PEM coatings has been limited due to problems associated with interlayer diffusion of
incorporated factors within PEM [146, 154, 167].
The novelty of the present study is the introduction of a biomimetic calcium phosphate
(bCaP) barrier layer into a poly-L-Lysine (PLLys) and poly-L-Glutamic acid (PLGlut) PEM
design. Calcium phosphate was chosen because of its biocompatibility, low cost, and ease of
manufacture. It was hypothesized that if the bCaP layer could prevent interlayer diffusion of
biological agents, then controlled, sequential delivery of multiple factors would be achieved.
This chapter reports the fabrication and characterization of bCaP-PEM coatings and the in vitro
assessment of the sequential delivery kinetics and bioactivity of two factors with opposing
activity (proliferative vs. cytotoxic) delivered from bCaP-PEM coatings. MC3T3-E1
osteoprogenitor cells were used for the cell culture evaluation assays and biological assays were
selected because they provide important information about the potential response of host
progenitor cells to implanted materials coated with bCaP-PEM.
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2.2 Materials and Methods
2.2.1 Design of the Sequential Delivery System
To prevent the issue of interlayer diffusion of multiple factors associated with a PEM-only
coating (Fig. 2.1A), a biomimetic calcium phosphate layer (bCaP) was incorporated into a
PLLys-PLGlut PEM system, (Fig. 2.1B). It is hypothesized that because of interlayer diffusion,
a PEM only coating would result in co-delivery (Fig. 2.1C), but introducing bCaP into the
delivery system would result in sequential delivery of multiple factors (Fig. 2.1D).
2.2.2 Material Fabrication
2.2.2.a Preparation of Biomimetic-CaP Disks
Twenty-two mm diameter plastic disks (NUNC, Rochester, NY) were sandblasted with 240-grit
aluminum oxide powder (Ivoclar Vivadent, Amherst, NY) to obtain a roughened surface
(TCPsb). Both sides were roughened. The sandblasted disks were cleaned by ultra sonication in
water and UV-sterilized prior to coating.
A two-step simulated body fluid (SBF) biomimetic calcium phosphate coating (bCaP)
protocol originally developed for metal substrates [118, 172-174] and modified for plastic disks
by the Kuhn lab [168], was utilized to form the bCaP layer. The coating procedure involves
immersion and incubation in two different solutions (Table 2.1): Solution A results in a thin
amorphous layer of CaP, Solution B, with less inhibitors of apatite formation, results in the
formation of mature apatite crystals as a second layer above the amorphous layer. Coatings were
prepared with either just solution A (CaP) or solutions A and B (bCaP). All reagents (SigmaAldrich) were used as received.
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To prepare Solution A, the inorganic salts in the following order were weighed and
dissolved in 800 ml sterile filtered MIlliQ water maintained at 37 ± 0.1°C with stirring: NaCl
(32.0 ± 0.001 g), MgCl2, 6H2O (1.216 ± 0.001 g), CaCl2, 2H2O (1.472 ± 0.001 g). The pH was
lowered to 4 by bubbling CO2 gas through the solution at a steady flow for about 5 min. Then
Na2HPO4, 2H2O (0.712 ± 0.001 g) and NaHCO3 (1.408 ± 0.001 g) were dissolved and CO2 gas
was continually bubbled through the solution until the pH was below 6.2. At this point the
solution was spilt in half between two smaller beakers (heated to 37°C), both capable of
submerging three custom-made sample holders, each designed to hold 6 disks vertically, about 1
mm apart. Vertical positioning was used to avoid the unwanted settling and attachment of any
large homogeneously nucleated particles on the disks [175]. The beakers were sealed with saran
wrap with 20–30 small holes in it to allow for gradual CO2 release, thus restricting homogeneous
nucleation/solution precipitation that occurs without a cover, and promoting the formation of the
thin amorphous CaP layer directly on the substrate disks. Each beaker was equipped with a stir
bar and was placed in a 37°C oven on a stir plate set to match the mixing during the solution
preparation (~130 rpm). After approximately 24 h, the samples were sonicated briefly in the
reacted Solution A. Prior to immersion in Solution B, the disks were gradually dehydrated by
being passed through a graded series of increasing concentrations of ethyl alcohol.
To prepare Solution B, NaCl (32.0 ± 0.001 g), MgCl2, 6H2O (0.240 ± 0.001 g), CaCl2,
2H2O (1.472 ± 0.001 g) were dissolved in 800 ml MilliQ water maintained at 50 ± 1°C followed
by CO2 gas bubbling to obtain a pH below 4.0. Na2HPO4, 2H2O (0.712 ± 0.001 g) and NaHCO3
(0.704 ± 0.001 g) were added and CO2 gas was bubbled through the solution until
supersaturation at a pH of 5.8–6.2 was reached. The solution was then split, the disks were
immersed, and the beakers sealed as before to limit homogeneous nucleation, and placed in a
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50°C oven. The process was allowed to proceed for at least 24 h with stirring, until the pH was >
7.8 at which time the samples were removed, sonicated briefly in the reacted Solution B, then
dehydrated in a series of graded ethanol. The samples were stored in a desiccator until further
use.
2.2.2.b Polyelectrolyte multilayer application
The PEM coatings were applied to the sandblasted plastic disks, CaP- and/or the bCaP-coated
disks by alternate 10 min dippings into 1 mg/ml poly-L-Glutamic acid (PLGlut-) or poly-LLysine (PLLys+) solutions (Sigma, St. Louis, MO), with seven saline rinses between each. This
dip-coating process was automated with the use of a histology-staining machine (Varistain 24-4,
Thermo Shandon, Loughborough, UK) and custom designed sample holders. Eight or thirty
bilayers (PLLys-PLGlut = 1 bilayer) were adsorbed on top of the disks. The coated disks were
UV-sterilized on both sides prior to cell culture.
2.2.2.c Factor Application
To demonstrate the ability of bCaP addition to PEM to prevent diffusion and delay access to an
embedded factor, a model cytotoxic agent antimycin A (AntiA) (213 μg/disk) (Sigma, St. Louis,
MO) was used. Prior to bCaP and/or PEM application, 10 μl of 40mM AntiA in ethanol (213
μg/disk) was adsorbed onto the sandblasted plastic surface, and allowed to dry; since AntiA was
allowed to completely dry to maximize binding. The disks were rinsed 3x with saline before
coating application. During the coating application the disks were protected from light.
To demonstrate sequential delivery from the bCaP-PEM coatings, a combination of a
proliferative factor, recombinant human fibroblast growth factor-2 (FGF-2) (150 ng/disk) (R &
D Systems, Minneapolis, MN), and the cytotoxic AntiA was used. The AntiA (213 μg/disk) was
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embedded beneath the coating. After AntiA adsorption, bCaP and PEM30 application, 375
ng/ml FGF-2 in saline was allowed to adsorb to the coated disks for 1hr, then rinsed 3x with
saline. Enzyme-linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN) testing
was performed and determined approximately 80% FGF-2 binds, (actual adsorbed dose ~120
ng/disk).
The coating procedure is summarized in Figure 2.2 including factor application, calcium
phosphate deposition, and PEM adsorption. Factor 1 represents FGF-2, the factor to be delivered
first, and Factor 2 represents AntiA, the embedded factor to be delivered at a later time point.
2.2.3 Characterization
2.2.3.a Scanning Electron Microscopy (SEM)
One CaP, bCaP, bCaP-PEM, and PEM coated disks from 3-6 different batches were examined to
characterize surface morphology and consistency. The microscopic morphology was
characterized using SEM (JSM - 5900LV, Jeol USA Inc. Peabody, MA). Disks were cut in half,
allowing examination of the coating cross-section and measurement of the coating thickness in
multiple locations.
2.2.3.b Energy Dispersive X-Ray Spectroscopy (EDS)
The elemental composition and Ca/P ratio of the bCaP coatings before and after PEM application
were determined with energy dispersive X-ray spectroscopy (FEI Teneo LVSEM and EDAX
SDD EDS). The accelerating voltage was 10 kV and the depth of X-ray interaction was
estimated to be 1 μm. At least 3–5 locations on each disk were analyzed at 1kX magnification for
an area scan, and 10kX for point analysis. Values were compared to those obtained from a
hydroxyapatite powder (Sigma, St. Louis, MO).
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2.2.3.c X-Ray Diffraction (XRD)
The crystal structure of the bCaP coating before and after PEM application was determined with
an X-ray diffractometer (Bruker D8 Advanced, Bruker AXS) using Cu Kα radiation at 40 kV and
44 mA over a 2θ range of 5–75◦ at a scan rate of 2°/min in steps of 0.02°. Sufficient material was
scraped from six representative disks to produce powder samples. The crystal structure was
identified by comparison to the hydroxyapatite standard and previously published patterns [168].
2.2.3 Cell Culture Assays
MC3T3-E1 mouse calvarial osteoprogenitor cells (ATCC, Manassas, VA) were cultured in
alpha-Minimal Essential Medium (α-MEM, No. 12571, Gibco BRL, Invitrogen), supplemented
with 10% fetal bovine serum (FBS), and 100 U/ml penicillin and 100 μg/ml streptomycin sulfate.
Medium was refreshed every 2–3 days until 80-90% confluent and split at a ratio of 1:8.
Passages 10–30 were routinely used. The cells were detached from tissue culture dishes with
0.25% trypsin and 1 mM EDTA (Invitrogen, Cat. No. 25200-056) at 37°C. Cells were counted
using an automated cell counter (Bio-Rad, TC20) with trypan blue staining to assess cell number
and viability prior to the cell proliferation assays.
The coated disks were sterilized prior to cell culture by exposure to UV light for 10 min
to each side of the disks. They were then placed into 12-well treated tissue culture plates
(Corning Inc., Corning, NY) and submerged in α-MEM medium for 30-45 min. MC3T3-E1s
were seeded at 1 or 4 x 104 cells/cm2 in culture medium and were incubated at 37°C and 5% CO2
for up to 7 days with medium changed every 3 days. Proliferative and cytotoxic effects of the
coatings on the cells were evaluated with LIVE® staining (Invitrogen Life Technologies, Grand
Island, NY) following the manufacturer’s protocol. Prior to LIVE® staining the disks were
transferred to new wells and washed with phosphate buffered saline solution (PBS) to remove
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non-adherent cells; LIVE® staining was prepared as instructed and applied to the disks, and then
incubated at room temperature for 30 min. After 30 min disks were flipped over and imaged at
100X magnification using an inverted microscope (TE300, Nikon) equipped with a camera
(Diagnostic Instruments), and imaging software (Spot Insight, Nikon). ImageJ was used for 3-5
images/well, analysis of 3-6 wells/group. Proliferation was quantified as average percent
fluorescent area via ImageJ analysis. Percent cell death was calculated by comparing the average
percent fluorescent area of the AntiA group to its AntiA-free control.
2.2.3.a Antimycin A Dose Response and Stability
The embedded factor (“Factor 2”) used to assess diffusion prevention was antimycin A (AntiA)
(Sigma, St. Louis, MO), known to be cytotoxic to MC3T3-E1 cells [176, 177]. To determine the
appropriate cytotoxic dose when delivered from a biomaterial surface a dose response study was
first conducted. The following doses of AntiA were absorbed in 10 μl volumes of ethanol to 12well treated tissue culture plates (Corning Inc., Corning, NY): 40 mM, 20 mM, 12 mM, 6 mM, 2
mM, 0.07 mM, and 0 mM (100% ethanol), n = 3 wells/dose. AntiA solution was allowed to
completely dry on the wells to maximize binding. After drying, wells were rinsed 3x with saline
and then placed in α-MEM medium for 30-45 min prior to plating. MC3T3-E1s were plated at 1
x 104 cells/cm2. Cytotoxic effects of the adsorbed doses on the cells were evaluated with LIVE®
staining after 24 h of culture. ImageJ analysis was performed.
To determine if the coating process inactivated the AntiA, 10 μl of 40mM AntiA in
ethanol (213 μg/disk) was adsorbed onto the sandblasted disks, allowed to dry, and then rinsed
3x with saline. N = 4 disks underwent the “PEM” processing but without PEM, meaning disks
were subjected to the automated dip procedure that normally would apply the polyelectrolytes
but only saline was used. N = 4 disks underwent conditions similar to the “bCaP” processing,
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meaning the disks were submerged in MilliQ water (rather than solution A or B) and left in the
oven at 37°C for 24 h, then at 50°C for 24 h. After “processing” disks were placed in 12-well
plates. Fresh AntiA adsorbed to sandblasted disks (213 μg/disk with 3x saline rinses, n = 4) was
used as a positive control. Sandblasted disks with no AntiA were used as the negative control (n
= 4). MC3T3-E1s were plated at 4 x 104 cells/cm2. Cytotoxic effects of the disks on the cells
were evaluated with LIVE® staining after 24 h of culture. ImageJ analysis was performed.
2.2.3.b Diffusion Studies
AntiA was used as “Factor 2” to evaluate if prevention of interlayer diffusion of an embedded
factor could be achieved by the addition of CaP and/or bCaP to PEM. Coatings were prepared as
previously described in section 2.2.2c. The following groups/coatings were used for the diffusion
studies and repeated at least 2x: TCPsb, TCPsb-AntiA, and TCPsb coated with CaP-PEM8,
AntiA-CaP-PEM8, CaP-PEM30, AntiA-CaP-PEM30, bCaP-PEM30, AntiA-bCaP-PEM30,
PEM30, and AntiA-PEM30. MC3T3-E1s were seeded at 1 or 4 x 104 cells/cm2 in culture
medium and were incubated at 37°C and 5% CO2 for up to 5 days. LIVE ® staining with ImageJ
analysis was performed.
2.2.3.c FGF-2 Dose Response
FGF-2 was selected as Factor 1 for evaluating the bCaP effects on diffusion. FGF-2 stimulates
MC3T3-E1 proliferation [36, 88, 178, 179], and has the opposite effect of Factor 2 (cytotoxic
AntiA) on the cells. The following doses of FGF-2 were adsorbed to bCaP-PEM30 coated disks,
0, 1.5, 15, and 150 ng/disk as previously described in section 2.2.2c. MC3T3-E1s were seeded at
4 x 104 cells/cm2 in culture medium and were incubated at 37°C and 5% CO2 for 1 day. LIVE ®
staining with ImageJ analysis was performed on day 1.

28

Emily Elizabeth Jacobs – University of Connecticut, 2016

2.2.3.d Bioactivity of Single Factor Delivery from bCaP-PEM30
The bioactivity of Factor 1 (150 ng/disk FGF-2) and Factor 2 (213 μg/disk AntiA) delivered
from bCaP-PEM30 coated disks were investigated individually. Coatings were prepared as
previously mentioned, and MC3T3-E1s were plated at 4 x 104 cells/cm2 in culture medium and
were incubated at 37°C and 5% CO2 for up to 5 days with medium changed on day 3. LIVE ®
staining with ImageJ analysis was performed on 4h, day 1, 2, 3, 4, and 5. All groups were
repeated twice.
2.2.3.e Sequential Delivery from bCaP-PEM30
The sequential delivery (AntiA-bCaP-PEM30-FGF2) coated disks and their controls (bCaPPEM30-FGF2) were prepared as previously mentioned. MC3T3-E1s were plated at 4 x 104
cells/cm2 in culture medium and were incubated at 37°C and 5% CO2 for up to 5 days with
medium changed on day 3. LIVE ® staining with ImageJ analysis was performed on 4h, day 1,
2, 3, 4, and 5. All groups were repeated at least twice.
2.2.4 Factor Release from bCaP-PEM30 Coatings
AntiA-bCaP-PEM30-FGF2 and bCaP-PEM30-FGF2 coatings were prepared on TCPsb. Coated
disks were incubated in culture medium at 37°C and 5% CO2 for 1 or 3 days without cells or
media changes. Release medium was collected at each time point and immediately frozen at 20°C. MC3T3-E1s were plated in a 96-well tissue culture treated plate (Becton Dickinson and
Company, Franklin Lakes, NJ) at 2.5 x 103cells/cm2. After 48 h of culture, 50% of the media in
each well was removed and replaced with thawed release medium (in triplicate). After an
additional 24 h of culture LIVE® staining and ImageJ were used to determine the effects of the
release medium on the culture. Enzyme-linked immunosorbent assay (ELISA, R&D Systems,
Minneapolis, MN) testing was also performed on FGF-2 group release samples.
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2.2.5 Statistical Analyses
Statistical significances were determined by unpaired t-tests and one-way ANOVA with Tukey
post-tests, with a p-value < 0.05 being considered statistically significant. Standard deviations
are shown in all figures.
2.3 Results
2.3.1 Characterization of the Coatings
SEM microscopy with EDS point analysis revealed some embedded aluminum oxide used for
sandblasting the disks present on the sandblasted plastic disks (Fig. 2.3A). The CaP coating
produced with Solution A only resulted in a uniformly deposited, thin, amorphous layer. The
CaP layer was so thin it could not be measured via SEM (Fig. 2.3B). The bCaP coating
produced with both solution A and solution B resulted in densely packed, nano-crystals that
completely coated the TCPsb. The average layer thickness measured via SEM was 5.8 + 1.8 μm
(Fig. 2.3C). The bCaP crystals became indistinguishable after PEM30 application with an
average bCaP-PEM30 coating thickness of 16.3 + 2.2 μm (Fig. 2.3D). PEM30 uniformly
adsorbed to the TCPsb, but the coating thickness was not measurable via SEM (Fig. 2.3E).
Energy dispersive x-ray spectroscopy (EDS) revealed Ca/P atomic ratios of 1.95 + 0.12
and 1.52 + 0.50 for bCaP before (Fig. 2.4A) and after PEM30 adsorption (Fig. 2.4B), neither of
which is statistically different than the Ca/P ratio of the hydroxyapatite powder, (1.71 + 0.04),
nor each other (Fig. 2.4C). EDS analysis of bCaP-PEM30 also confirmed the presence of carbon
and nitrogen due to the polyelectrolyte compositions. The crystal structure of the bCaP was
identified as poorly crystalline/nanocrystallline hydroxyapatite by XRD (Fig. 2.4D). The term
poorly crystalline/nanocrystalline is used due to the observed peak broadening [168]. After PEM
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adsorption, the bCaP crystal structure became less crystalline as evident by even further peak
broadening (Fig. 2.4E).
2.3.2 Antimycin A Dose Response and Stability
The antimycin A dose response study revealed a 50% inhibitory concentration (IC50) of 3.08
mM (Fig. 2.5). The 40 mM dose (213 μg/disk) resulted in almost complete cell death; therefore,
it was selected to be used in all studies that use AntiA because it was necessary to observe
significant cell death to ensure there were no question the cells were accessing the AntiA.
To ensure the coating procedure did not inactivate the AntiA, antimycin’s stability was
tested after being treated with multiple saline rinses (“PEM” processing), or when treated with
MilliQ water and heat (“bCaP” processing). All AntiAs tested resulted in significant cell death
within 24 h of culture as compared to the negative control, TCPsb with no AntiA (Fig. 2.6, ****
p < 0.0001).

Furthermore there were no statistically significant differences between the

processed AntiAs compared to the fresh/normal AntiA indicating AntiA retains its cytotoxic
activity after coating application.
2.3.3 Diffusion Studies
The first attempt at producing a coating that could prevent the interlayer diffusion of embedded
213 μg/disk AntiA was to use an amorphous CaP layer and 8 bilayers of PEM (CaP-PEM8). Day
1 LIVE® staining of MC3T3-E1s cultured on TCPsb coated with AntiA, AntiA embedded under
PEM8, and AntiA embedded under CaP-PEM8 resulted in 91.9 + 2.3 %, 79.6 + 5.2 %, and 42.4
+ 2.8 % cell death respectively, relative to their AntiA-free controls (Fig. 2.7A). Though CaPPEM8 was significantly better than the PEM8 coating at preventing diffusion of AntiA (**** p
< 0.0001), it did not provide enough delayed access to the embedded AntiA as indicated by the
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significant difference between AntiA-CaP-PEM8 and CaP-PEM8 at day 1 (Fig. 2.7B, **** p <
0.0001).
The next attempt to improve delayed access to the embedded 213 μg/disk AntiA was to
increase the number of PEM bilayers adsorbed to the CaP layer from 8 to 30. This resulted in no
difference between AntiA-CaP-PEM30 and CaP-PEM30 on day 1, however, no drop in LIVE®
staining with extended time in culture was observed (Fig. 2.8).
It was then decided to increase the thickness and crystallinity of the CaP layer by using
both Solution A and Solution B to make bCaP in attempts to prevent diffusion and completely
block access to the AntiA in the first day. MC3T3-E1s cultured for one day on TCPsb coated
with 213 μg/disk AntiA resulted in a significant drop in % LIVE® stained area as compared to
its AntiA-free control (TCPsb vs. TCPsb+AntiA, Fig. 2.9A, **** p < 0.0001), and this equated
to 96.6 + 1.2 % cell death (Fig. 2.9B); this is visualized in Fig. 2.9C vs. D. MC3T3-E1s cultured
for one day on TCPsb coated with 213 μg/disk AntiA embedded under 30 bilayers of PEM
resulted in a significant drop in % LIVE® stained area as compared to its AntiA-free control
(PEM30 vs. PEM30+AntiA, Fig. 2.9A, *** p < 0.001), and this equated to 79.5 + 4.2 % cell
death (Fig. 2.9B); this is visualized in Fig. 2.9E vs. F. MC3T3-E1s cultured for one day on
TCPsb coated with 213 μg/disk AntiA embedded under bCaP and 30 bilayers of PEM resulted in
no difference in % LIVE® stained area as compared to its AntiA-free control (bCaP-PEM30 vs.
bCaP-PEM30+AntiA, Fig. 2.9A), and this equated to -6.7 + 10.6 % cell death (Fig. 2.9B); this is
visualized in Fig. 2.9G vs. H. Percent cell death is negative for this group because the day 1
LIVE® staining on the AntiA-bCaP-PEM30 was slightly higher than on the bCaP-PEM30
control, (Fig. 2.9A).
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2.3.4 Bioactivity of Single Factor Delivery from bCaP-PEM30
Figure 2.10 displays the results of day 1 LIVE ® of MC3T3-E1s cultured on bCaP-PEM30
coated disks with various doses of FGF-2. Because the 150 ng/disk dose of FGF-2 had the most
significant effect on cell proliferation (**** p < 0.0001), it was selected as the dose to be used
for all future coating studies.
Factor 1 (150 ng/disk FGF-2) and Factor 2 (213 μg/disk AntiA) location within the bCaPPEM30 coating and the expected cell access profiles are illustrated in Figure 2.11. Bio-active
FGF-2 was successfully delivered from bCaP-PEM30 coated disks (bCaP-PEM30-FGF2) as
indicated by the significant increase in LIVE® staining of the MC3T3-E1 cultures on day 1 and
the remaining time points in the study, as compared to the FGF-free control (bCaP-PEM30) (Fig.
2.12). No differences were observed at 4 h (Fig. 2.13). Active AntiA was successfully delivered
from bCaP-PEM30 coated disks (AntiA-bCaP-PEM30) as evident by the significant decrease in
MC3T3-E1 proliferation on day 3 as compared to the AntiA-free control (bCaP-PEM30) (Fig.
2.14).
2.3.5 Factor Release from bCaP-PEM30 Coatings
Release medium collected from bCaP-PEM30-FGF-2 coated disks incubated without cells for 1
and 3 days had no significant proliferative effect on MC3T3-E1s as compared to controls
cultured in normal medium, indicating no FGF-2 release (Fig. 2.15, D1 and D3 –A/+F). Release
medium collected after 1 and 3 days incubation with AntiA-bCaP-PEM30-FGF-2 had no
cytotoxic effect on cells as compared to release medium collected after 1 and 3 days incubation
with bCaP-PEM30-FGF-2 indicating no AntiA release (Fig. 2.15, D1 and D3 +A/+F).

33

Emily Elizabeth Jacobs – University of Connecticut, 2016

2.3.6 Sequential Delivery of Multiple Factors from bCaP-PEM30 Coatings
Active FGF-2 (150 ng/disk) was delivered from bCaP-PEM30 coated disks with or without
embedded AntiA as evident by the significant increase in day 1 MC3T3-E1 LIVE® staining of
the FGF-2 groups as compared to their FGF-2-free controls, (Fig 2.16A). No differences in
LIVE® stained area were observed between cells cultured on bCaP-PEM-FGF2 and AntiAbCaP-PEM30-FGF2 for time points 4h, day 1 and day 2, as both groups were exposed to FGF-2
and AntiA was successfully being blocked (Fig. 2.16B, 3.3C); by day 3 a significant decrease in
LIVE® staining between groups was observed indicating AntiA delivery, (Fig. 2.16B, 3.3C). At
day 4, the cells that survived the AntiA exposure started to recover and continued to proliferate
through the duration of the study (Fig. 2.16C).
2.4 Discussion
There is a need for new biomaterials to deliver bioactive growth factors in a sequential manner to
maximize their reparative effects. In this study the development of a novel biomimetic calcium
phosphate/polyelectrolyte multilayer coating for the sequential delivery of multiple biological
agents was reported. In vitro studies were used to demonstrate the ability of the bCaP barrier
layer to prevent the interlayer diffusion problem associated with PEM films. Two different
factors were delivered without loss of activity, and the delivery of factors from the coating was
cell-mediated. Most importantly sequential delivery of multiple factors was demonstrated.
The polyelectrolyte multilayer films formed by PLLys and PLGlut occurs by exponential
growth with “in and out” diffusion of the polyelectrolytes that allow interlayer diffusion of
incorporated factors [146]. As the film is exposed to a polyanion (-) solution, the polycation (+)
within the film will diffuse to the surface allowing for more binding sites for the polyanion. Vice
versa will occur during the next step when the polycation solution is being applied; because of
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this growth pattern, any incorporated factor within the film will constantly be rearranged during
the layer build up resulting in a blended architecture lacking controlled order, therefore
uncontrolled delivery [154] (Fig. 2.17). To prevent this diffusion from occurring a biomimetic
calcium phosphate layer was incorporated into the poly-L-Lys/poly-L-Glut acid PEM design to
act as a barrier and keep the factors in separate locations within the coating so sequential delivery
could be possible.

The combined use of polyelectrolytes and CaP has previously been

investigated for bone tissue engineering, but not as a multifactor delivery system [157, 180, 181].
It was observed that the addition of an amorphous CaP layer could significantly improve
interlayer diffusion of embedded antimycin A as compared to a PEM only coating, however,
42% of the cells still accessed at least some of the AntiA within the first 24 h resulting in their
death (Fig 2.7A). The CaP-PEM8 coating would be insufficient for sequential delivery because
the embedded Factor 2 can still be accessed immediately. Increasing the number of PEM
bilayers in attempts to prevent cellular access to the embedded AntiA had little to no effect,
again suggesting that a CaP-PEM30 coating would also be insufficient for potential sequential
delivery. The data indicates that the MC3T3-E1s can access the embedded AntiA within the first
24 h and implies the CaP and PEM30 coatings were too thin; in fact they were not capable of
being measured via SEM (Fig. 2.3B, E).
To completely block access of the cells to the embedded AntiA for at least 1 day, it was
hypothesized that increasing the thickness of the CaP layer would not only prevent the diffusion
of the AntiA up and into the PEM layers, but delay access to the AntiA. It was shown that 30
bilayers of PEM delays access to embedded AntiA better than no coating at all, but it still results
in significant cell death within 24 h (Fig. 2.9B). PEM alone could not inhibit the embedded
AntiA from diffusing up and through the bilayers, resulting in immediate access of the cells to
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the cytotoxic factor. However, when the AntiA is embedded beneath the bCaP layer and 30
bilayers of PEM, almost no cell death occurs by 24 h (Fig. 2.9B). These results confirm that a
PEM30 only coating would be insufficient for sequential delivery because it cannot inhibit
interlayer diffusion; but the addition of bCaP to the PEM30 coating successfully inhibits
diffusion, and prevents access at day 1, suggesting the potential of this coating design for
sequential, multifactor delivery.
The PEM system has the ability to release and maintain the bioactivity of the
incorporated factors. Because bioactive proteins are directly integrated in the architecture of the
film based on electrostatic interactions and do not require covalent bonding [151, 152], their
secondary structures remain close to their native form and this retains their biological activity
[111].

Individual and combinations of bio-active growth factors have been successfully

delivered from PEM systems [160, 163, 165-167]; more specifically, TGFβ1, BMP-2, VEGF,
and BMP-2 antagonist (Noggin) have all been delivered from poly-L-Lysine/poly-L-Glutamic
acid PEM coatings and retain their bioactivity [161, 162, 164]. Other delivery systems, such as
polyethylene glycol (PEG) hydrogels, can inactivate the protein during the immobilization
process (crosslinking) via damaging the growth factor’s functional groups [27].
It was shown in the present study that delivery of FGF-2 from the bCaP-PEM coating
causes significant increase in MC3T3-E1 proliferation confirming that the biological activity of
FGF-2 is retained and being delivered in the therapeutic range (Fig. 2.12). It should be noted that
FGF-2 did not aid in initial cell attachment, as evident by the lack of significant differences in
LIVE® staining of the MC3T3-E1s after 4 h of culture (Fig. 2.13A). It was only after 24 h that
an increase was observed (Fig. 2.13B) indicating that the FGF-2 is stimulating the proliferation
of the MC3T3-E1s. Literature suggests that FGF-2 will aid in initial cell attachment [182],
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however it is hypothesized that the PEM bilayers act as a reservoir for the FGF-2; even though
the FGF-2 is adsorbed as the outermost layer of the coating, it is believed that the FGF-2 will
diffuse down into the PEM layers. Because of this, cells may not be immediately in contact with
the FGF-2, which could explain why no differences are observed after 4h; however, after 24 h
and time for the cells to start to degrade the PEM, they gain access to the FGF-2 that stimulates
their proliferation. The cytotoxic activity of AntiA is also retained after it is accessed on day 3
of culture on the AntiA-bCaP-PEM30-FGF2 group (Fig. 2.14).
One of the most attractive features of the bCaP-PEM delivery system is its ability to
locally deliver factors directly to cells and thereby restrict therapeutic action to a small domain of
tissue. Poly-L-Lysine/poly-L-Glutamic acid PEM allows for local delivery of incorporated
factors because release depends upon cell-mediated enzymatic degradation of the PEM layers
[150], and not diffusion of the factors out of the coating. In systems where the growth factor is
simply mixed with a carrier, or adsorbed on the surface without an additional coating, burst
release of the growth factor leads to diffusion away from the target site and it can be
enzymatically digested or deactivated [6], or can require supraphysiological doses of growth
factor that lead to off-target, unwanted side effects, (INFUSE Bone Graft (Medtronic) [19, 30].
Encapsulating the growth factor within a liposome or particle can extend the release and prevent
the deactivation of the growth factor [130, 183]; however, the delivery system is still dependent
on diffusion of the particles out of a secondary material therefore local, targeted delivery to only
the cells of interest can be difficult to achieve. In the present studies there was no indication of
release of neither FGF-2, nor AntiA without cells present. There was a lack of measurable
quantities of FGF-2 in the release medium and no proliferative or cytotoxic effects of the release
medium collected from disks incubated without cells was observed (Fig. 2.15). Due to the cell-
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mediated degradation of the bCaP-PEM coating, lower doses of growth factor can be used
because delivery is not dependent on diffusion. AntiA has low solubility in solutions other than
ethanol; therefore it was unlikely the AntiA would diffuse into an aqueous release medium,
which may be why no indication of release without cells present was observed. However, AntiA
has a known 50% inhibitory concentration against MC3T3-E1 cells of 70 μM when in solution
[176]; in the present studies a 40 mM dose of AntiA before bCaP-PEM30 coating was used.
Even if a fraction of this dose were diffusing out of the coating into the media, it would be
expected to have a cytotoxic effect on the cells.
The mechanism of which the MC3T3-E1 cells degrade the bCaP to access the AntiA
remains unclear. In the Kuhn’s lab previous work, it was shown that after 21 days of MC3T3-E1
cultured on the bCaP coating, the coating remained intact [168]. It is hypothesized that rather
than physically degrading the bCaP layer, the MC3T3-E1s are actually using their processes to
push through small cracks in the coating and access the AntiA. It is known that osteoblasts
cultured in three-dimensions [184] or on the surface of bone will form long processes [185, 186].
From the LIVE® staining in the present studies, it is evident the MC3T3-E1s have processes in
two-dimensions along the surface of the coating; it is hypothesized these processes also extend
down through the coating and that is how the AntiA is being accessed.
Sequential delivery of multiple bioactive factors with complete blocking of access to the
embedded factor for three days was demonstrated by introducing a bCaP barrier layer into a 30bilayer poly-L-lysine/poly-L-glutamic acid PEM system (Fig. 2.16). As previously mentioned,
Min et al. used a similar barrier layer strategy for attempted sequential delivery from a PEM
coating and demonstrated successful staggered release of first an antibiotic and then BMP-2.
Burst release of BMP-2 was prevented and sustained release was demonstrated for several days,
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but measurable released BMP-2 was still present at their earliest time points [156]. In a dualpurpose delivery system such as this, where the factors do not influence each other and serve two
separate functions (prevent infection, aid in bone healing), this delivery profile is acceptable.
However in a system where the growth factors are being delivered in combination for one
function, such as the use of FGF-2 and BMP-2 for enhanced bone regeneration, sequential
delivery may be necessary because these growth factors can influence the effect of the other.
2.5 Conclusions
This study showed that a poly-L-Lysine/poly-L-Glutamic acid PEM only coating results in
interlayer diffusion and immediate access to an embedded factor, proving that this PEM only
system could not provide sequential delivery of multiple factors. The addition of amorphous CaP
to PEM prevented some interlayer diffusion of an embedded factor, however significant access
to the factor was occurring with 24 h, suggesting it would be incapable of sequential delivery.
The addition of nanocrystalline bCaP to PEM (bCaP-PEM30) completely prevented unwanted
interlayer diffusion of the embedded factor and enabled cell-mediated sequential delivery of
multiple factors. Sequential delivery of a proliferative factor, fibroblast growth factor-2, followed
by a cytotoxic factor, antimycin A was demonstrated. Both factors retained their bioactivity in
vitro. The addition of the bCaP layer to the PEM design resulted in delayed access of the
embedded antimycin A out to 3 days when cultured with MC3T3-E1 cells. This delivery system
has potential to endow biomaterial scaffolds with the ability to mimic natural biological
processes that involve a sequential delivery profile activated by cell degradation of matrix.
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Figure 2.1 Schematic representation of interlayer diffusion of Factors 1 and 2 in a PEM only
coating (A), compared to prevention of interlayer diffusion of Factors 1 and 2 with the addition
of bCaP to the PEM coating (B). The theoretical co- and sequential delivery profiles from a PEM
only coating (C) and a bCaP-PEM coating (D) respectively.
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Table 2.1 Nominal chemical composition of Solutions A and B in mM. Solution B contains less
inhibitors of apatite crystal formation (red text).
Inorganic Salt

Solution A

Solution B

Reagent Chemical

Na+

733.5

733.5

NaCl

Mg2+

7.5

1.5

MgCl2  6H2O

Ca2+

12.5

12.5

CaCl2  2H2O

Cl-

720

720

HPO42-

5

5

Na2HPO4  2H2O

HCO3-

21

10

NaHCO3
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Figure 2.2 Sandblasted disk coating procedure for diffusion studies. Step 1: Factor 2 (AntiA) is
adsorbed. Step 2A: disks are submerged in Solution A to deposit a thin layer of amorphous
calcium phosphate (CaP). Step 2B: disks are submerged in Solution B to deposit nanocrystalline
calcium phosphate, (bCaP). Step 3: 8-30 bilayers of PEM are applied by automated dip
procedure. Step 4: Factor 1 (FGF-2) is adsorbed.
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Figure 2.3 Scanning electron microscopy images of the surface morphology and cross-section of
a sandblasted disk (A), and the sandblasted disks coated with: amorphous calcium phosphate
CaP (B), nanocrystalline calcium phosphate bCaP (C), nanocrystalline calcium phosphate and 30
bilayers of PEM (D), and 30 bilayers of PEM (E). B and E coating thickness was not measurable
via SEM. bCaP thickness = 5.8 + 1.8 μm (C). bCaP-PEM30 thickness = 16.3 + 2.2 μm (D).
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Figure 2.4 EDS analysis of the bCaP deposited on the TCPsb before (A) and after PEM30
adsorption (B), revealed Ca/P atomic ratios of 1.95 + 0.12 and 1.52 + 0.50 respectively, not
statistically different from the hydroxyapatite powder (1.71 + 0.04) nor each other. The
composition of the bCaP coating was identified as poorly crystalline/nanocrystalline
hydroxyapatite by XRD (C). After PEM adsorption the bCaP became less crystalline (D).
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Figure 2.5 AntiA dose response curve. The adsorbed AntiA IC50 was found to be 3.08 mM
(black arrow). The dose of AntiA selected to use for all studies was 40 mM (red arrow).
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Figure 2.6 Percent LIVE® stained area of MC3T3-Es cultured for 1 day on sandblasted disks
coated with normal AntiA (TCPsb-AntiA), AntiA after “PEM” processing, AntiA after “bCaP”
processing, and no AntiA (TCPsb). AntiA = 213 μg/disk. (**** p < 0.0001).
ANOVA P value < 0.0001
Tukey's multiple comparisons Mean
test
Diff.

95% CI of diff.

Significant?

Summary

TCPsb vs. TCPsb-AntiA

34.26

28.20 to 40.32

Yes

****

TCPsb
vs.
TCPsb-AntiA 34.35
"PEM" Processed

28.29 to 40.41

Yes

****

TCPsb
vs.
TCPsb-AntiA 30.43
"bCaP" Processed

24.36 to 36.49

Yes

****
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Figure 2.7 Day 1 percent cell death of MC3T3-E1s cultured on TCPsb coated with AntiA,
AntiA embedded under PEM8, and AntiA embedded under CaP-PEM8 relative to their AntiAfree controls (A). Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with
CaP-PEM8 (blue) and AntiA embedded under CaP-PEM8 (red) for days 1, 3, and 5 (B). AntiA =
213 μg/disk. (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
Figure 2.7A
ANOVA P value < 0.0001
Tukey's
comparisons test

multiple Mean Diff.

95% CI of diff.

Significant?

Summary

12.30

5.067 to 19.53

Yes

**

AntiA vs. AntiA-CaP-PEM8 49.50

42.27 to 56.73

Yes

****

AntiA-PEM8
CaP-PEM8

29.97 to 44.43

Yes

****

AntiA vs. AntiA-PEM8

vs.

AntiA- 37.20

Figure 2.7B
Unpaired t test
Day 1 P value

0.0152

Day 3 P value

0.0029

Day 5 P value

0.0008
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Figure 2.8 Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with CaPPEM30 (blue) and Anti embedded under CaP-PEM30 (red) for days 1, 3, 5, and 7. AntiA = 213
μg/disk. (* p < 0.05, ** p < 0.01).
Unpaired t test
Day 5 P value

0.0441

Day 7 P value

0.0030
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Figure 2.9 Day 1 % LIVE® stained area of MC3T3-E1s cultured on AntiA with no coating
compared to its AntiA-free control, AntiA embedded under PEM30 compared to its AntiA-free
control, and AntiA embedded under bCaP-PEM30 compared to its AntiA-free control (A), (****
p value < 0.0001). The calculated day 1 % cell deaths of AntiA, AntiA-PEM30, and AntiAbCaP-PEM30 relative to their AntiA-free controls (B), (* p value < 0.05, *** p value < 0.001,
**** p value < 0.0001). Fluorescent images of LIVE® staining of MC3T3-E1s cultured on
TCPsb (C) vs. TCPsb coated with AntiA (D), PEM30 (E) vs. AntiA-PEM30 (F), and bCaPPEM30 (G) vs. AntiA-bCaP-PEM30 (H). Scale bar = 250 μm.

50

Emily Elizabeth Jacobs – University of Connecticut, 2016

Figure 2.9A
ANOVA P value < 0.0001
Tukey's multiple comparisons test Mean Diff. 95% CI of diff. Significant? Summary
TCPsb
+ AntiA

vs.

TCPsb 34.26

27.76 to 40.76

Yes

****

PEM30
+ AntiA

vs.

PEM30 14.84

7.894 to 21.79

Yes

****

Figure 2.9B
ANOVA P value < 0.0001
Tukey's
comparisons test

multiple Mean
Diff.

95% CI of diff.

Significant?

Summary

TCPsb+ AntiA vs. PEM30 17.11
+ AntiA

3.297 to 30.92

Yes

*

TCPsb+ AntiA vs. bCaP- 103.3
PEM30+ AntiA

89.50 to 117.1

Yes

****

PEM30+ AntiA vs. bCaP- 86.20
PEM30+ AntiA

71.44 to 101.0

Yes

****
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Figure 2.10 MC3T3-E1 FGF-2 dose response day 1 LIVE® staining. (* p < 0.05, ** p < 0.01,
**** p < 0.0001). The 150 ng FGF-2 dose was selected to use for all studies.
ANOVA P value < 0.0001
Tukey's multiple comparisons test

Mean
Diff.

95% CI of diff.

Significant? Summary

bCaP-PEM30 vs. bCaP-PEM30-FGF2 -8.097
(15 ng)

-12.74 to -3.452

Yes

**

bCaP-PEM30 vs. bCaP-PEM30-FGF2 -21.94
(150 ng)

-26.58 to -17.30

Yes

****

bCaP-PEM30-FGF2 (1.5 ng) vs. bCaP- -4.779
PEM30-FGF2 (15 ng)

-9.423
0.1343

bCaP-PEM30-FGF2 (1.5 ng) vs. bCaP- -18.62
PEM30-FGF2 (150 ng)

-23.27 to -13.98

Yes

****

bCaP-PEM30-FGF2 (15 ng) vs. bCaP- -13.84
PEM30-FGF2 (150 ng)

-18.49 to -9.199

Yes

****

to

- Yes

*
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Figure 2.11 Schematic representation of Factor 1 (A) and Factor 2 (B) location within the bCaPPEM30 coating. The theoretical immediate, and delayed delivery profiles of Factor 1 (C) and
Factor 2 (D) respectively.
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Figure 2.12 LIVE® stained area of MC3T3-E1s cultured on bCaP-PEM30-FGF2 (blue) and
bCaP-PEM30 (green) for up to 5 days (A), (** p < 0.01, *** p < 0.001, **** p < 0.0001) (FGF2 = 150 ng/disk). Fluorescent images of day 1 LIVE® staining of MC3T3-E1s cultured on
TCPsb coated with bCaP-PEM30-FGF2 (B) and bCaP-PEM30 (C). Scale bar = 250 μm.
Unpaired t test
Day 1 P value

0.0013

Day 2 P value

< 0.0001

Day 3 P value

< 0.0001

Day 4 P value

< 0.0001

Day 5 P value

0.0003
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Figure 2.13 Percent LIVE® stained area of MC3T3-E1s cultured on TCPsb coated with bCaPPEM30 (green, -A/-F) and bCaP-PEM30-FGF2 (blue, -A/+F) at 4h (A), and day 1 (B), (** p <
0.01). Fluorescent images of LIVE® staining of MC3T3-E1s cultured on TCPsb coated with
bCaP-PEM30 and bCaP-PEM30-FGF2 after 4 h (C, D) and 1 day (E, F).
Unpaired t test
Day 1 P value

0.0013
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Figure 2.14 LIVE® stained area of MC3T3-E1s cultured on bCaP-PEM30 (green) and AntiAbCaP-PEM30 (red) for up to 5 days (A), (* p < 0.05, ** p < 0.01, *** p < 0.001) (AntiA = 213
μg/disk). Fluorescent images of day 3 LIVE® staining of MC3T3-E1s cultured on TCPsb coated
with bCaP-PEM30 (B) and AntiA-bCaP-PEM30 (C). Scale bar = 250 μm.
Unpaired t test
Day 2 P value

0.0306

Day 3 P value

0.0001

Day 4 P value

0.0031
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Figure 2.15 Percent LIVE® staining of MC3T3-E1s cultured in day 1- or day 3-release medium
collected from bCaP-PEM30-FGF-2 (-A/+F, blue) or AntiA-bCaP-PEM30-FGF-2 (+A/+F,
ornage) coated disks incubated at 37°C without cells, (FGF-2 = 150 ng/disk, AntiA = 213
μg/disk).
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Figure 2.16 Day 1 LIVE® stained area of MC3T3-E1s cultured on the FGF-2 groups (+F)
compared to their FGF-2-free controls (-F) (FGF-2 = 150 ng/disk) (A), (*** p < 0.001, **** p <
0.0001). Percent LIVE® stained area of MC3T3-E1 cells cultured on bCaP-PEM30-FGF2 (blue)
and AntiA-bCaP-PEM30-FGF2 (orange) over time (B), (**** p < 0.0001). Fluorescent images
of LIVE® staining of MC3T3-E1s cultured on bCaP-PEM30-FGF-2 (-A/+F), and AntiA-bCaPPEM30-FGF-2 (+A/+F), at time points 4 h, days 1-5 (C). Scale bar = 250 μm.
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Figure 2.16A
ANOVA P value < 0.0001
Tukey's multiple comparisons test

Mean
Diff.

95% CI of Significan
diff.
t?

Summa
ry

bCaP-PEM30 vs. bCaP-PEM30-FGF2

-16.40

-22.65 to - Yes
10.15

****

AntiA-bCaP- -11.89

-18.13 to - Yes
5.637

***

AntiA-bCaP-PEM30
PEM30-FGF2

vs.

Figure 2.16B
Unpaired t test
Day 3 P value

< 0.0001

Day 4 P value

< 0.0001

Day 5 P value

< 0.0001
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Figure 2.17 Schematic representation of “in and out” diffusion and exponential growth of
hydrophilic polyelectrolytes during layer-by-layer build up of the PEM film (A). Resulting
interlayer diffusion of multiple factors within the PEM layers (B) and theoretical co-delivery of
factors (C).
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Chapter 3
Tunable Delivery Kinetics of Multiple Factors from Biomimetic Calcium Phosphate/PEM
Coatings
3.1 Introduction
The ability to sequentially delivery multiple factors is an important feature of new biomaterials
to stimulate successful tissue regeneration. This is because natural healing and regeneration is
tightly controlled by a cascade of growth factors and signaling molecules, that all act at specific
times during development and repair [4]. Many biological systems need specific growth factor
exposure on a time scale of days to weeks, so it is important that new biomaterials offer specific
tunability so the delivery of growth factors from the material can best match the natural process,
resulting in enhanced tissue regeneration. For example, during bone fracture healing, the first
stage of healing, acute inflammation, typically last around three days [38]; during this time
monocytes, mesenchymal stem cells (MSCs), and subsequent osteoprogenitor cells are recruited
to the defect site. For successful healing to occur, it is important that inflammation subside and
these progenitor cells have a chance to proliferate and fill the defect before differentiating. Bone
morphogenetic protein-2 (BMP-2) is considered one the key growth factors responsible for
osteoprogenitor differentiation [36], and it has been shown that BMP-2 delivered too early can
inhibit in vitro osteogenesis [104]. Therefore it is critical that this stage of fracture healing
completes before delivering the differentiation agent from the biomaterial.
In

the

previous

chapter,

it

was

shown

that

the

biomimetic

calcium

phosphate/polyelectrolyte multilayer coatings made with 30 bilayers of poly-L-Lysine/poly-Lglutamic acid (bCaP-PEM30), could successfully sequentially delivery two factors in vitro to
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osteoprogenitor cells, with access to the embedded factor occurring on day 3 of culture. It was
also shown that the delivery of the factors was based on the cell-mediated degradation of the
coating and not diffusion of the factors out. It is expected that the delivery kinetics in vivo would
most likely be accelerated due to the presence of other cell-types, such as macrophages, that are
known to be capable of rapid resorption of PLLys-PLGlut PEM materials [121]. This motivated
the work of this chapter, which is focused on altering the PEM and bCaP portions of the bCaPPEM30 coating to further delay access to the embedded factor when cultured with
osteoprogenitor cells. The PEM component of the coating was altered by increasing the number
of bilayers, shown to increase the degradation time of the film in vitro [114], and by using the Denantiomers of the polyelectrolytes, poly-D-Lysine and poly-D-Glutamic acid, also shown to
slow the cellular degradation of the film [150]. The bCaP layer was altered by increasing time in
the simulated body fluid solutions used to produce the layer [168], which is a demonstrated
method for increasing the thickness of the bCaP layer [172]. In addition, because delivery of
factors from the bCaP-PEM30 coating is cell-mediated, and monocytes/macrophages are one of
the first cell-types that would interact with the coating in vivo [119], cellular assays were
conducted with the mouse macrophage cell line, RAW 264.7, to determine the in vitro delivery
kinetics of multiple factors from the bCaP-PEM30 coating.
This chapter reports the in vitro cell culture assessment of the sequential delivery kinetics
of two factors with opposing activity (proliferative vs. cytotoxic) delivered from bCaP-PEM
coatings with alternations made to the PEM portion of the coating, or to the bCaP layer of the
coating. In addition, changes in factor delivery kinetics resulting from changing the cell type
interacting with the coating, were used to investigate the cell-mediated degradation of the
coating. MC3T3-E1 mouse osteoprogenitor cells and RAW 264.7 mouse macrophage cells were
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used for the cell culture evaluation assays because they provide important information about the
potential response of host progenitor cells (MC3T3-E1) and immune response (RAW 264.7) to
implanted materials coated with bCaP-PEM.
3.2 Materials and Methods
3.2.1 Factor Application
To demonstrate delivery kinetics from the bCaP-PEM coatings, a combination of a proliferative
factor, recombinant human fibroblast growth factor-2 (FGF-2) (150 ng/disk) (R & D Systems,
Minneapolis, MN), and a model cytotoxic agent antimycin A (AntiA) (213 μg/disk) (Sigma, St.
Louis, MO) was used. It was expected that the FGF-2 would immediately stimulate cellular
proliferation, and then at a later time point the cells would access the AntiA and die, indicating
successful bio-active delivery of the factors from the coating. Prior to coating application, 10 μl
of 40mM antimycin A in ethanol (213 μg/disk) was adsorbed onto the sandblasted plastic surface
and was allowed to completely dry to maximize binding. The disks were rinsed 3x with saline
before coating application. During the coating application the disks were protected from light
because AntiA is light sensitive. After AntiA adsorption, and coating application, 375 ng/ml
FGF-2 in saline was allowed to adsorb to the coated disks for 1hr, then rinsed 3x with saline.
Enzyme-linked immunosorbent assay (ELISA, R&D Systems, Minneapolis, MN) testing was
performed and determined approximately 80% FGF-2 binds, (actual adsorbed dose ~120
ng/disk).
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3.2.2 Tuning bCaP-PEM30 Delivery Kinetics
3.2.2.a Increasing Number of PEM Bilayers
AntiA (213 μg/disk) was adsorbed and bCaP was applied as previously described in Ch. 2. 102
bilayers of PEM were applied (PLLys-PLGlut = 1 bilayer). This dip-coating process was
automated with the use of a histology-staining machine (Varistain 24-4, Thermo Shandon,
Loughborough, UK) and custom designed sample holders. All polyelectrolyte solutions and
saline rinses were replaced every 30 bilayers. After PEM102 application, disks were UVsterilized on both sides.

FGF-2 (150 ng/disk) was adsorbed as previously described. The

sequential delivery group (AntiA-bCaP-PEM102-FGF2) and its AntiA-free control (bCaPPEM102-FGF2) were each tested only once to evaluate the feasibility of this approach towards
tuning delivery kinetics, and the results should be considered for pilot purposes only.
3.2.2.b Use of “D” Enantiomers
AntiA (213 μg/disk) was adsorbed and bCaP was applied as previously described in Ch. 2. 30
bilayers of PEM were applied by alternate 10 min dippings into 1 mg/ml poly-D-Glutamic acid
(PDGlut-) or poly-D-Lysine (PDLys+) solutions (Sigma, St. Louis, MO), with seven saline
rinses between each. After PEMD30 application, disks were UV-sterilized on both sides. FGF-2
(150 ng/disk) was adsorbed as previously described. The sequential delivery group (AntiAbCaP-PEMD30-FGF2) and its AntiA-free control (bCaP- PEMD30-FGF2) were each tested only
once to evaluate the feasibility of this approach towards tuning delivery kinetics, and the results
should be considered for pilot purposes only.
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3.2.2.c Adjusting Time in Solution B to Change bCaP Layer Thickness
AntiA (213 μg/disk) was adsorbed as previously described. During bCaP deposition, Solution A
was applied as normal, (~24 h at 37°C); time in Solution B was either increased or decreased
from the normal ~24 h at 50°C. Increased times were extended to 48 h (bCaP(48)) in Solution B,
decreased times were dropped to 7 h (bCaP(7)) in Solution B. After bCaP(7) or bCaP(48) were
deposited, PEM30 and FGF-2 (150 ng/disk) were applied as previously described in Ch. 2. The
sequential delivery group using 7 h in Solution B (AntiA-bCaP(7)-PEM30-FGF2) was tested
only once to evaluate the feasibility of this approach towards tuning delivery kinetics, and the
results should be considered for pilot purposes only. The sequential delivery group (AntiAbCaP(48)-PEM30-FGF2) and its AntiA-free control (bCaP(48)-PEM30-FGF2) prepared using
48 h in Solution B were each tested at least two times.
bCaP(7) and bCaP(48) coated disks were examined to characterize surface morphology
and consistency. The microscopic morphology was characterized using SEM (JSM - 5900LV,
Jeol USA Inc. Peabody, MA). Disks were cut in half, allowing examination of the coating crosssection and measurement of the coating thickness with SEM.
3.2.2.d MC3T3-E1 Assays for Assessing Delivery Kinetics
MC3T3-E1 mouse calvarial osteoprogenitor cells (ATCC, Manassas, VA) were cultured in
alpha-Minimal Essential Medium (α-MEM, No. 12571, Gibco BRL, Invitrogen), supplemented
with 10% fetal bovine serum (FBS), and 100 U/ml penicillin and 100 μg/ml streptomycin sulfate.
Cells were maintained and prepared for cell-culture assays as previously described in Ch. 2.
The coated disks were placed into 12-well tissue culture plates and submerged in α-MEM
medium for 30-45 min. MC3T3-E1s were seeded at 4 x 104 cells/cm2 in culture medium and
were incubated at 37°C and 5% CO2 for 4h, 1, 2, 3, 4, 5, 6, and 7 days, (medium changed on day
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3 and 6). LIVE® staining and ImageJ analyses were performed to determine a measure of cell
number as previously described in Ch. 2.
3.2.3 RAW 264.7 Assays for Evaluation of bCaP-PEM30 Delivery Kinetics
3.2.3.a Preparation of bCaP-PEM30 disks
Biomimetic calcium phosphate (bCaP) and poly-l-Lysine/poly-l-Glutamic acid PEM coatings
(bCaP-PEM30) were prepared on sandblasted tissue culture plastic disks (TCPsb) as described in
Ch. 2. AntiA (213 μg/disk), bCaP-PEM30, and FGF-2 (150 ng/disk) were applied as previously
described (AntiA-bCaP-PEM30-FGF2). Control coated disks were also prepared (bCaP-PEM30FGF2, bCaP-PEM30, AntiA-bCaP-PEM30).
3.2.3.b RAW 264.7 Assays for Assessing Delivery Kinetics
RAW 264.7 mouse monocyte macrophage cells (ATCC, Manassas, VA) were cultured in
DMEM high glucose, pyruvate medium, (No. 11995, Gibco BRL, Invitrogen), supplemented
with 10% fetal bovine serum (FBS), and 100 U/ml penicillin and 100 μg/ml streptomycin sulfate.
Medium was refreshed every 2–3 days until 70-80% confluent and split at a ratio of 1:8.
Passages 10–30 were routinely used. The cells were detached from tissue culture dishes by use of
a cell-scraper. Cells were counted using an automated cell counter (Bio-Rad, TC20) with trypan
blue staining to assess cell number and viability prior to the cell proliferation assays.
The coated disks were sterilized prior to cell culture by exposure to UV light for 10 min
to each side of the disks. They were then placed into 12-well treated tissue culture plates
(Corning Inc., Corning, NY) and submerged in α-MEM medium for 30-45 min. RAW 264.7s
were seeded at 7.9 x 103 or 3 x 104 cells/cm2 in culture medium and were incubated at 37°C and
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5% CO2 for up to 3 days. LIVE® staining and ImageJ analyses were performed as previously
described in Ch. 2. All groups reported for each cell seeding density were performed twice.
3.2.3 Statistical Analyses
Statistical significances were determined by unpaired t-tests and one-way ANOVA with Tukey
post-tests, with a p-value < 0.05 being considered statistically significant. Standard deviations
are shown in all figures.
3.3 Results
3.3.1 Tuning bCaP-PEM30 Delivery Kinetics
3.3.1.a Increasing Number of PEM Bilayers
MC3T3-E1s cultured on AntiA-bCaP-PEM102-FGF2 resulted in a significant decrease in
LIVE® staining on day 3 compared to its AntiA-free control (bCaP-PEM102-FGF2), (Fig.
3.1A), (* p < 0.05). LIVE® staining of MC3T3-E1s cultured on the control bCaP-PEM30-FGF2
disks were significantly higher on days 3 and 5 as compared to cells on bCaP-PEM102-FGF2
disks, (Fig. 3.1B), (*** p < 0.001). Significant difference in LIVE® staining were observed
between MC3T3-E1s cultured on the control AntiA-bCaP-PEM30-FGF2 disks and AntiA-bCaPPEM102-FGF2 disks on days 3 and 5, (Fig 3.1C), (* p < 0.05, ** p < 0.01).
3.3.1.b Use of “D” Enantiomers
MC3T3-E1s cultured on AntiA-bCaP-PEMD30-FGF2 resulted in a significant decrease in
LIVE® staining on day 3 compared to its AntiA-free control (bCaP-PEMD30-FGF2), (Fig.
3.2A), (**** p < 0.0001). LIVE® staining of MC3T3-E1s cultured on the control bCaP-PEM30FGF2 disks were significantly higher on days 3 and 5 as compared to cells on bCaP-PEMD30FGF2 disks, (Fig. 3.2B), (* p < 0.05, ** p < 0.01). Significant difference in LIVE® staining
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were observed between MC3T3-E1s cultured on the control AntiA-bCaP-PEM30-FGF2 disks
and AntiA-bCaP-PEMD30-FGF2 disks on day 5, (Fig. 3.2C), (* p < 0.05).
3.3.1.c Adjusting Time in Solution B to Change bCaP Layer Thickness
Schematic representations of bCaP-PEM30 made with bCaP after 7 h in Solution B (bCaP(7)),
after 24 h in Solution B (the normal bCaP procedure, bCaP(24)), and after 48 h in Solution B
(bCaP(48)) are illustrated in Fig. 3.3. Scanning electron microscopy revealed that all bCaPs
produced formed densely packed, nano-crystals, (Fig. 3.4). bCaP(7), bCaP(24), and bCaP(48)
resulted in coating thicknesses of 1.8 + 0.7 μm, 5.8 + 1.8 μm, and 24.0 + 2.4 μm respectively.
Culturing MC3T3-E1s on AntiA-bCaP(7)-PEM30-FGF2 resulted in similar % LIVE® stained
area as culturing the cells on AntiA-bCaP(24)-PEM30-FGF2, however culturing the cells on
AntiA-bCaP(48)-PEM30-FGF2 resulted in a significant increase in LIVE® staining on day 3 as
compared to the other two groups (Fig. 3.5). Culturing MC3T3-E1s on AntiA-bCaP(48)-PEM30FGF2 resulted in a significant decrease in percent LIVE® stained area on day 3 and throughout
the remaining time points in the study as compared to cells cultured on its AntiA-free control
(bCaP(48)-PEM30-FGF2) (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001), (Fig. 3.6),
therefore AntiA was still being initially accessed on day 3; however unlike cells cultured on
AntiA-bCaP(24)-PEM30-FGF2 where after day 3 the cells start to recover (Fig. 3.6A,B), cells on
AntiA-bCaP(48)-PEM30-FGF2 continue to decrease from day 3 through day 7 (Fig. 3.6C,D). It
should be noted that the data obtained for days 5-7 came from a separate study than the one that
produced data for time points 4h, days 1-4; this is because the number of disks that can be
produced at once is limited and can only provide enough replicates for a maximum of 5 time
points. Theoretical delivery profiles of FGF-2 and AntiA from bCaP(24)-PEM30 and bCaP(48)PEM30 are illustrated in Fig. 3.7.
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3.3.2 RAW 264.7 Assays for Evaluation of bCaP-PEM30 Delivery Kinetics
Increasing the RAW 264.7 seeding density from 7.9k to 30k cells/cm2 significantly increased
percent LIVE® stained area within 4 hours of culture and throughout all time points of the study
when cultured on bCaP-PEM30-FGF2 (Fig.3.8A). Increasing the RAW 264.7 seeding density
from 7.9k to 30k cells/cm2 significantly decreased percent LIVE® stained area within 4 hours of
culture and throughout all time points of the study when cultured on AntiA-bCaP-PEM30-FGF2
(Fig.3.8B). This indicates that AntiA is being accessed immediately when RAW cells are seeded
at 30k cells/cm2. At the lower seeding density, no differences between cells cultured on bCaPPEM30-FGF2 and AntiA-bCaP-PEM30-FGF2 were observed at 4 h, day 1, or day 2 (Fig.3.9)
indicating the AntiA is not being accessed at these time points. However, at the higher seeding
density, a significant decrease in LIVE® staining was observed on the AntiA-bCaP-PEM30FGF2 group compared to its AntiA-free control at 4 h and throughout the duration of the study
(Fig. 3.10); this indicates that sequential delivery is no longer occurring because there is no
delayed access to the embedded AntiA. A significant increase in percent LIVE® stained area
after 4 h of culture for RAW cells seeded at 30k cells/cm2 on bCaP-PEM30-FGF2 (blue, -A/+F)
was observed as compared to bCaP-PEM30 (green, -A/-F, ** p < 0.01) and AntiA-bCaPPEM30-FGF2 (orange, +A/+F, *** p < 0.001), (Fig. 3.11A); Addition of FGF-2 to bCaPPEM30 stimulated initial RAW cell attachment and proliferation within 4 h. Addition of FGF-2
to AntiA-bCaP-PEM30 (orange) resulted in significant decreases in RAW cell LIVE® stained
area at 4 h, and days 1-3 as compared to the FGF-2-free control (red), (* p < 0.05, ** p < 0.01),
(Fig. 3.11 B).

69

Emily Elizabeth Jacobs – University of Connecticut, 2016

3.4 Discussion
The ability to control the timing and rate of delivery of factors from a biomaterial is of critical
importance for the success of the biomaterial when its aim is to replicate a natural biological
process. In this study the use of a novel biomimetic calcium phosphate/polyelectrolyte multilayer
coating was used to demonstrate tunable delivery kinetics of multiple biologically active factors.
In vitro cell culture studies were used to demonstrate cell-mediated, sequential delivery of a
proliferative factor (FGF-2) and a cytotoxic factor (AntiA) from the bCaP-PEM30 coating with
alterations made to the bCaP thickness or the PEM composition. Change of delivery kinetics due
to change in cell type from pre-osteoblast progenitor to monocyte/macrophage was also
demonstrated.
The first attempt at increasing time of access to the embedded factor was to increase the
number of PEM bilayers from 30 to 102. Increasing the number of PEM layers has been shown
to increase the thickness of the film and time to degrade the film [114]. Increasing the number of
PLLys-PLGlut bilayers resulted in AntiA still being accessed on day 3 (Fig. 3.1A), and no
significant change in MC3T3-E1 proliferation with time when cultured on bCaP-PEM102-FGF2,
(Fig. 3.1B). The inability of the cells to grow on the coating without AntiA could be due to
inhibited burst delivery of FGF-2 or the increased concentration of poly-L-Lysine within the
coating. PLLys is known to be cytotoxic [116, 117], and it is believed that increasing the number
of PEM bilayers exceeded a tolerable level of PLLys for the MC3T3-E1 cells; therefore this is
not a viable strategy for improving the sequential delivery profile.
The next attempt to increase the amount of time to access the embedded factor was to use
the D-enantiomers of the polyelectrolytes, poly-D-Lysine and poly-D-Glutamic acid. Other
groups have attempted tuning cellular access of protein in the same 30-bilayer PEM system by
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increasing the ratio of D- to L-enantiomer polyelectrolytes within the film (shown to slow the
cellular degradation of the film); this resulted in delayed access to the protein for an additional 6
h [150]. In the present study, AntiA access was still being observed on day 3 (Fig. 3.2A); this is
most likely due to the very short-term (hours) tune-ability of the D-enantiomer approach. Again,
the cells observed slight inhibited growth on bCaP-PEMD30-FGF2 as compared to the bCaPPEM30-FGF2 control (Fig. 3.2B). Though the D-enantiomer approach did not significantly
changed access kinetics to the AntiA, it did appear to inhibit the delivery kinetics of the FGF-2.
Not surprisingly, altering the composition or number of PEM bilayers within the coating
only seemed to change the delivery kinetics of the FGF-2, which is adsorbed into the PEM
layers. Another strategy to delay release of an embedded factor commonly employed with PEM
systems is to covalently cross-link the polyelectrolytes. Wood et al. showed a delay up to 25 h of
release of an embedded factor with the use of a single thermally cross-linked poly(allylamine
hydrochloride)(PAH)/poly(acrylic acid) (PAA) layer; however the cross-linking procedure
required the material to be heated to 215°C for 20 min which would denature most biological
agents [154]. Hsu et al. showed similar results by cross-linking chitosan/poly(b-l-malic acid) via
copper-free click chemistry, and could delay release of an embedded factor up to 24 h [187].
Many biological systems need specific growth factor exposure on a time scale of days to weeks,
not hours, therefore these short-term tuning strategies (increasing PEM bilayers, using Denantiomers) are not sufficient for delaying access to the embedded factor nor for in vivo
purposes.
The final attempt at tuning the delivery kinetics of the embedded factor was to increase
the thickness of the bCaP layer by altering the time the samples spent in Solution B of the SBF
CaP method during bCaP deposition in the bCaP-PEM30 procedure. As the literature suggested
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[118, 172-174], increasing or decreasing this time resulted in an increase or decrease in the bCaP
layer thickness (Fig. 3.4). Depositing a thinner bCaP(7) coating resulted in similar delivery
kinetics of the embedded AntiA as using the normal bCaP(24) layer (Fig. 3.5). Depositing a
thicker bCaP(48) layer resulted in a significant increase in LIVE® staining on day 3 as compared
to bCaP(7) and bCaP(24) (Fig. 3.5). Culturing MC3T3-E1s on AntiA-bCaP(48)-PEM30-FGF2
resulted in a significant decrease in percent LIVE® stained area on day 3 and throughout the
remaining time points in the study as compared to cells cultured on its AntiA-free control
(bCaP(48)-PEM30-FGF2) (Fig. 3.6); therefore AntiA was still being initially accessed on day 3;
however unlike cells cultured on AntiA-bCaP(24)-PEM30-FGF2 where after day 3 the cells start
to recover (Fig. 3.6A,B), cells on AntiA-bCaP(48)-PEM30-FGF2 continue to decrease from day
3 through day 7 (Fig. 3.6C,D). It is hypothesized that increasing the bCaP layer thickness
changed the AntiA delivery from burst (observed with bCaP(24)) to potential sustained delivery
(with bCaP(48)), hence why the cells continue to die over the course of multiple days. These
theoretical delivery profiles of FGF-2 and AntiA from bCaP(24)-PEM30 and bCaP(48)-PEM30
are illustrated in Fig. 3.7.
It was shown in chapter 2 that the bCaP-PEM30 coating delivery of factors is cellmediated as indicated by the lack of proliferative or cytotoxic effects observed when cells were
cultured with collected release medium (from coated disks incubated without cells) (Fig. 2.15).
These results lead to the hypothesis that using a cell-type more capable of degradation or
resorption would result in faster delivery kinetics of the embedded factor. Because monocytes
are one of the first cells recruited to the area when tissue is damaged or infected [119], these cells
may be some of the first to interact with the bCaP-PEM30 coating in vivo. RAW 264.7 mouse
monocyte macrophage cells (RAW) were therefore chosen for evaluating sequential delivery
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kinetics of the bCaP-PEM coatings as a comparison to the pre-osteoblast MC3T3-E1 cells that
are present at slightly later stages in the bone repair process. Two different RAW cell densities
were tested on the bCaP-PEM30 coatings, 7.9k and 30k cells/cm2. As expected, the increased
cell seeding density resulted in increased LIVE® staining within 4 h on the control coatings
(bCaP-PEM30-FGF2, no AntiA, Fig. 3.8A). Surprisingly, the increased cell seeding density did
not increase 4 h LIVE® staining of RAW cells cultured on AntiA-bCaP-PEM30-FGF2 coatings
(Fig. 3.8B); in fact it resulted in a significant decrease in LIVE® staining, suggesting the RAW
cells may be accessing the AntiA within the first 4 h of culture. When the RAW cells are seeded
at lower density (7.9k cells/cm2), no differences in LIVE® staining are observed between the
AntiA group and the AntiA-free control at the 4 h, day 1 and day 2 time points (Fig. 3.9);
indicating AntiA is being blocked until access on day 3, similar to the osteoprogenitor cells.
However, when the seeding density is increased to 30k cells/cm2, a significant decrease in
LIVE® staining is observed at the 4 h time point when comparing the AntiA group to its AntiAfree control (Fig. 3.10). This is much faster AntiA access than the day 3 access observed for the
MC3T3-E1s cultured on the same coating, and as a result suggests that the bCaP-PEM30 coating
can only provide co-delivery to macrophages at this density, as compared to the desired
sequential delivery observed with the osteoprogenitors (Fig. 3.12). These results demonstrate that
not only is the type of cells interacting with the coating important, but the number of cells as
well; increasing the cell number resulted in faster degradation of the coating.
The two seeding densities selected to be used in the present studies were chosen to
possibly mimic a normal, acute inflammation response (lower seeding density), as compared to a
more severe, chronic inflammation response that could lead to a foreign body reaction (higher
seeding density). The progression of events in inflammation and the foreign body response to an
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implanted biomaterial requires the migration of monocytes/macrophages to the implant site
(acute inflammation) and then the further propagation of chemoattractive signals such as PDGF,
TNF-α, IL-6, granulocyte colony-stimulating factor (GCSF), and macrophage colony stimulating
factor (MCSF) to call more macrophages to the wound site leading to chronic inflammation
[188, 189]. At the lower seeding density, a 3 day delay to the embedded AntiA was occurring
suggesting that a normal acute inflammatory response during the bone fracture healing process
would offer some delay to the embedded factor in vivo. The higher seeding density that may
associate to more severe, chronic inflammation response to the implanted biomaterial, offered no
delay to the embedded AntiA meaning a severe reaction to the bCaP-PEM30 coating in vivo,
would not be able to provide sequential delivery. Though our goals in vivo are to influence the
osteoprogenitor cells with growth factor delivery, it is important to consider the effects of
inflammation, therefore monocyte/macrophage cells, on the coating degradation and ultimate
timing of growth factor delivery. A better understanding of cell type and number delivery
kinetics of the bCaP-PEM coating would help better predict in vivo delivery kinetics.
Macrophages are capable of degrading non-cross-linked polyelectrolyte multilayer films
[122]; more specifically, RAW 264.7 cells have previously been shown to digest PLLys-PLGlut
multilayer particles [121], therefore it was expected that the RAW cells could degrade the PEM
portion of the bCaP-PEM coating. Similar to the MC3T3-E1 osteoprogenitor cells, the RAW
cells cannot dissolve or resorb the bCaP layer when in their undifferentiated state, as used in the
present studies, (not differentiated into osteoclasts) [190]. It is therefore speculated that the rapid
access to the embedded AntiA when the macrophages are seeded at the higher density is the
result of their ability to degrade the PEM layers faster than the osteoprogenitors. Similar to the
MC3T3-E1s, it is predicted that the RAW cells access the AntiA by being able to migrate
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through micro-cracks in the bCaP layer to access the AntiA. FGF-2 has been shown to stimulate
macrophage recruitment [191]; Fig. 3.11A shows that addition of FGF-2 to bCaP-PEM30
without AntiA causes a significant increase in initial cell attachment (4h, blue vs. green);
however, when AntiA is present in the coating, addition of FGF-2 causes a significant decrease
in LIVE® staining at the 4 h time point (Fig. 3.11B). These results indicate that FGF-2 is
increasing initial cell attachment and that the increase in cells increases coating degradation as
compared to the FGF-2-free control (Fig. 3.11B).
3.5 Conclusions
The bCaP-PEM coating is capable of local, cell-mediated delivery to both osteoprogenitor cells
and macrophages. This means that the bCaP-PEM coating has the potential provide controlled,
local delivery of growth factors in vivo, at the early stages of bone fracture healing. Increasing
the number of PEM bilayers (30 to 102) within the coating could not further delay
osteoprogenitor access to the embedded AntiA, but potentially inhibited the delivery kinetics of
the FGF-2. Changing the chemical composition of the polyelectrolytes (L- to D- enantiomers)
also could not further delay osteoprogenitor access to the embedded AntiA, but did hinder the
delivery kinetics of the FGF-2. Increasing the thickness of the bCaP coating (~24 μm) from the
normal ~6 μm did not change the initial timing of access to the embedded AntiA, but did change
the delivery of AntiA from burst to sustained delivery over the course of 4 days to the
osteoprogenitor cells. Changing the cell type used to evaluate delivery kinetics from the coating
from osteoprogenitors to macrophages significantly increased access time to the embedded
factor. When the macrophages were seeded at a low density (7.9k cells/cm2) the bCaP-PEM30
coating provided 3 days delayed access to the embedded factor, similar to the osteoprogenitors.
When the macrophages were seeded at a high density (30k cells/cm2) the bCaP-PEM30 coating
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failed to provide any delayed access to the embedded factor.

These results highlight the

importance of cell type and number when evaluating delivery kinetics from a cell-mediated
delivery system. Understanding the macrophage response prior to the osteoprogenitor interaction
with bCaP-PEM30 will better predict the in vivo response to the implanted bCaP-PEM30 coated
scaffold.
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Figure 3.1 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP-PEM102-FGF2
(orange checker) as compared to cells cultured on bCaP-PEM102-FGF2 (blue checker) on days
1, 3, and 5 (A), (* p < 0.05). Percent LIVE® stained area of MC3T3-E1s cultured on the control
bCaP-PEM30-FGF2 as compared to cells on bCaP-PEM102-FGF2, (B), (*** p < 0.001).
Percent LIVE® stained area of MC3T3-E1s cultured on the control AntiA-bCaP-PEM30-FGF2
as compared to cells on AntiA-bCaP-PEM102-FGF2, (C), (* p < 0.05, ** p < 0.01). AntiA =
213 μg/disk, FGF-2 = 150 ng/disk.
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Figure 3.1A
Unpaired t test
Day 3 P value

0.0202

Figure 3.1B
Unpaired t test
Day 3 P value

0.0003

Day 5 P value

0.0004

Figure 3.1C
Unpaired t test
Day 3 P value

0.0003

Day 5 P value

0.0004
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Figure 3.2 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP-PEMD30-FGF2
(orange stripes) as compared to cells cultured on bCaP-PEMD30-FGF2 (blue stripes) on days 1,
3, and 5 (A), (**** p < 0.0001). Percent LIVE® stained area of MC3T3-E1s cultured on the
control bCaP-PEM30-FGF2 as compared to cells on bCaP-PEMD30-FGF2, (B), (* p < 0.05, **
p < 0.01). Percent LIVE® stained area of MC3T3-E1s cultured on the control AntiA-bCaPPEM30-FGF2 as compared to AntiA-bCaP-PEMD30-FGF2, (C), (* p < 0.05). AntiA = 213
μg/disk, FGF-2 = 150 ng/disk.
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Figure 3.2A
Unpaired t test
Day 3 P value

< 0.0001

Figure 3.2B
Unpaired t test
Day 3 P value

0.0100

Day 5 P value

0.0360

Figure 3.2C
Unpaired t test
Day 5 P value

0.0319
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Figure 3.3 Schematic representations of bCaP-PEM30 coatings made with bCaP prepared by 7 h
in Solution B (A), normal or 24 h in Solution B (B), and 48 h in Solution B (C).
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Figure 3.4 Scanning electron microscopy images of the surface morphology and cross-section of
bCaP prepared by 7 h in Solution B (A), normal or 24 h in Solution B (B), and 48 h in Solution B
(C). bCaP(7) thickness = 1.8 + 0.7 μm, bCaP(24) thickness = 5.8 + 1.8 μm, and bCaP(48)
thickness = 24.0 + 2.4 μm.
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Figure 3.5 Percent LIVE® stained area of MC3T3-E1s cultured on AntiA-bCaP(7)-PEM30FGF2, AntiA-bCaP(24)-PEM30-FGF2, and AntiA-bCaP(48)-PEM30-FGF2 on time points 4 h,
days 1-4 (A), (** p < 0.01). Fluorescent images of MC3T3-E1s cultured on AntiA-bCaP(7)PEM30-FGF2, AntiA-bCaP(24)-PEM30-FGF2, and AntiA-bCaP(48)-PEM30-FGF2 (B). AntiA
= 213 μg/disk, FGF-2 = 150 ng/disk.
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ANOVA P value = 0.0014
Tukey's multiple comparisons test

Mean
Diff.

95% CI of Signific
diff.
ant?

Summ
ary

AntiA-bCaP(7h)-PEM30-FGF2
bCaP(48h)-PEM30-FGF2

vs.

AntiA- -12.92

-20.32 to - Yes
5.528

**

AntiA-bCaP(24h)-PEM30-FGF2
bCaP(48h)-PEM30-FGF2

vs.

AntiA- -13.31

-20.22 to - Yes
6.390

**
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Figure 3.6 Percent LIVE® stained area of MC3T3-E1s cultured on bCaP(24)-PEM30-FGF2 (A/+F) and AntiA-bCaP(24)-PEM30-FGF2 (+A/+F) (A) with corresponding fluorescent images
of cells (B), (**** p < 0.0001). (Note, this data is from Fig. 3.3 and is being shown for
reference). Percent LIVE® stained area of MC3T3-E1s cultured on bCaP(48)-PEM30-FGF2 (A/+F) and AntiA-bCaP(48)-PEM30-FGF2 (+A/+F) (C) with corresponding fluorescent images
of cells (D), (* p < 0.05, ** p < 0.01*** p < 0.001, **** p < 0.0001). (Note, data obtain for
Days 5, 6 and 7 were obtained from a separate experiment). Scale bar = 250 μm. AntiA = 213
μg/disk, FGF-2 = 150 ng/disk.
Figure 3.6 A, see Figure 2.16B statistics
Figure 3.6B
Unpaired t test
Day 3 P value

0.0304

Day 4 P value

0.0037
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Day 5 P value

< 0.0001

Day 6 P value

< 0.0001

Day 7 P value

< 0.0001
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Figure 3.7 Theoretical delivery profiles of FGF-2 and AntiA from bCaP(24h)-PEM30
demonstrating burst delivery of AntiA (A) and bCaP(48h)-PEM30 demonstrating sustained
delivery of AntiA (B).
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Figure 3.8 Percent LIVE® stained area of RAW 264.7 s cultured on bCaP-PEM30-FGF2 (A/+F) (A), and AntiA-bCaP-PEM30-FGF2 (+A/+F) (B) at seeding densities of 7.9k or 30k
cells/cm2 (* p < 0.05, ** p < 0.01). Fluorescent images of the cells at 4 h of culture (C). Scale
bar = 250 μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk.
Figure 3.8A
Unpaired t test
4 h P value

0.0084

Day 1 P value

0.0118

Day 3 P value

0.0141
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Figure 3.8B
Unpaired t test
4 h P value

0.0146

Day 1 P value

0.0023

Day 3 P value

0.0162
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Figure 3.9 Percent LIVE® stained area of RAW 264.7 cells cultured on bCaP-PEM30-FGF2 (A/+F) and AntiA-bCaP-PEM30-FGF2 (+A/+F) seeded at 7.9k cells/cm2 (A), (* p < 0.05).
Fluorescent images of the cells at 4 h, 1 day, 2 days and 3 days of culture (B). Scale bar = 250
μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk.
Unpaired t test
Day 1 P value

0.0211

Day 3 P value

0.0380
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Figure 3.10 Percent LIVE® stained area of RAW 264.7 cells cultured on bCaP-PEM30-FGF2 (A/+F) and AntiA-bCaP-PEM30-FGF2 (+A/+F) seeded at 30k cells/cm2 (A), (* p < 0.05, ** p <
0.01, *** p < 0.001). Fluorescent images of the cells at 4 h, 1, 2, and 3 days of culture (B). Scale
bar = 250 μm. AntiA = 213 μg/disk, FGF-2 = 150 ng/disk.
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Unpaired t test
4 h P value

0.0231

Day 1 P value

0.0002

Day 2 P value

0.0003

Day 3 P value

0.0056
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Figure 3.11 Percent LIVE® stained area of RAW 264.7 cells seeded at 30k cells/cm2 on bCaPPEM30 (green, -A/+F), bCaP-PEM30-FGF2 (blue, -A/+F), AntiA-bCaP-PEM30 (red, +A/-F),
and AntiA-bCaP-PEM30-FGF2 (orange, +A/+F) at 4 h of culture, (A). Percent LIVE® stained
area of RAW 264.7s seeded at 30k cells/cm2 on AntiA-bCaP-PEM30 (red), and AntiA-bCaPPEM30-FGF2 (orange) at 4 h, and days 1-3, (B). (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p
< 0.0001). AntiA = 213 μg/disk, FGF-2 = 150 ng/disk.
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Figure 3.11A
ANOVA P value = 0.0002
Tukey's multiple comparisons test Mean Diff. 95% CI of diff.

Significant? Summary

-A/-F vs. -A/+F

-2.458

-3.651 to -1.265 Yes

**

-A/+F vs. +A/+F

3.307

2.113 to 4.500

***

Yes

Figure 3.11B
Unpaired t test
4 h P value

0.0346

Day 1 P value

0.0060

Day 2 P value

0.0019

Day 3 P value

< 0.0001
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Figure 3.12 The theoretical sequential delivery profile of FGF-2 and AntiA from bCaP-PEM30
cultured with osteoprogenitor cells (MC3T3-E1s at 40k cell/cm2) (A), as compared to the codelivery of factors from bCaP-PEM30 cultured with macrophages (RAW 264.7a at 30k
cells/cm2) (B).
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Chapter 4
Sequential Delivery of FGF-2 and BMP-2 from Biomimetic Calcium Phosphate/PEM Coatings
for In Vivo Osteogenesis
4.1 Introduction
Roughly 6.8 million patients each year seek medical attention in the United States for bone
fractures (American Academy of Orthopaedic Surgeons). With modern treatment methods, most
bone fractures heal without any problems. However, a small, but significant proportion of broken
bones do not heal even with the best surgical or non-surgical treatments and this can lead to a
delayed- or non-union. Several factors can increase the risk of failed bone fracture healing
including: complicated/severe breaks, older age, poor nutrition, smoking, infection, and diseases
such as anemia, osteoporosis, vitamin D deficiencies, and diabetes, (American Academy of
Orthopaedic Surgeons). Treatment methods for large nonunions include the use of bone grafts or
bone graft substitutes. Autogenous and allogenic bone grafts have desirable osteoconductive and
osteoinductive properties, with autografts being considered the gold standard for treating these
types of defects [192, 193]. These methods provide scaffolding for patient’s bone to heal across
the nonunion/defect but lack the chemical signals and growth factors normally present to
stimulate natural bone regeneration and can result in insufficient healing, especially when the
autograft is taken from a patient with the increased risk factors that result in poor healing to
begin with.
There are a number of growth factors involved in bone healing, however bone
morphogenetic protein-2 (BMP-2) is the main one used clinically for bone repair. This is
because BMP-2 is one of the main growth factors responsible for initiating the differentiation of
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osteoprogenitors into osteoblasts leading to new bone formation [36]. BMP-2 delivered via a
collagen sponge (INFUSE Bone Graft, Medtronic, FDA approved) significantly enhances bone
formation and successful spinal fusion, [28]; however its use has been limited due to
complications with the required high dose of BMP-2 necessary for adequate bone formation.
These complications include severe inflammation, ectopic bone formation, osteolysis, seroma
formation, and possible increase in the risk of malignancy, [19, 30]. These problems stem from
the collagen sponge’s inability to contain the supraphysiologic dose of BMP-2 in the local tissue
environment and control its release. There is a need to refine the delivery and improve the
efficacy of BMP-2 so that it can be locally delivered in lower doses, with less risk of
complications.
Another growth factor necessary for bone healing, fibroblast growth factor 2 (FGF-2),
has been shown to increase proliferation, migration, and bone morphogenetic protein 2 (BMP-2)
sensitivity of osteoprogenitor cells when delivered at early time points [36, 78], and to inhibit
osteoblast differentiation at later stages [88]. The synergistic combination of FGF-2 with BMP-2
has shown promise as a means to reduce the BMP-2 dose necessary for bone formation [93, 97].
Growth factors have different effects on natural bone regeneration depending on the
developmental stage of the fracture healing process they are present during; therefore, sequence
of delivery is important to optimize growth factor activity and healing. Too much and/or late
stage exposure of FGF-2 at the same time as BMP-2 has been shown to reduce the amount of in
vitro and in vivo bone formation [90, 93, 194]. BMP-2 delivered too early can also inhibit in
vitro osteogenesis [104]. The benefit of sequential delivery of FGF-2 (early) and BMP-2 (late)
has been further shown through growth factor spiking during in vitro osteogenesis studies [88,
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90], providing additional motivation for the development of biomaterial systems for sequential
delivery.
This chapter focuses on the use of a biomimetic calcium phosphate, poly-L-Lysine/polyL-Glutamic acid (bCaP-PEM) coating applied to the commercially available bone graft substitute
Healos® (DePuy Synthes Spine, Raynham, MA) to sequentially deliver FGF-2 and BMP-2 in a
mouse calvarial defect model. It is hypothesized that early delivery of FGF-2 will stimulate the
proliferation of osteoprogenitor cells, and delayed delivery of BMP-2 will stimulate the
osteoprogenitor cells to differentiate into functioning osteoblasts, and this sequential delivery
profile will enhance in vivo BMP-2 stimulated bone formation.
4.2 Materials and Methods
4.2.1 Design of Sequential Delivery System
For all in vivo testing a calcium phosphate layer was precipitated prior to a PLLys-PLGlut PEM
application for delivery of BMP-2 only (Fig. 4.1A) or BMP-2and FGF-2 (Fig. 4.2B). The
theoretical delivery profiles of the single- and sequential- delivery coatings are illustrated in Fig.
4.1C and D respectively. For the in vivo studies, two different coating architectures were used:
amorphous calcium phosphate with 8 bilayers of PEM (CaP-PEM8), or nanocrystalline calcium
phosphate with 30 bilayers of PEM (bCaP-PEM30).
4.2.2 Material Fabrication
4.2.2.a Preparation of CaP-PEM8 coated Healos®
Healos® (DePuy Synthes Spine, Raynham, MA) was trimmed to a thickness ~ 1mm, then
scaffolds were cut out with a 3.5 mm biopsy punch (Integra Miltex, York, PA). Scaffolds were
UV-sterilized for 10 min on each side prior to factor adsorption. A 0.5 μg dose of recombinant
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human bone morphogenic protein 2 (BMP-2, R & D Systems, Minneapolis, MN) was applied to
the Healos® scaffolds by adding 2 μl of 250 μg/ml stock made in PBS to each scaffold and
allowing it to adsorbed for 1 h at room temperature.
After BMP-2 adsorption each scaffold was placed in a 1.5 ml micro-centrifuge tube and 1
ml of SBFx5 Solution A (prepared as described in Ch. 2) that is used to precipitate an amorphous
CaP layer on the scaffold was added to each tube. Tubes were left open and covered in parafilm
with 8-10 small holes poked through the parafilm. Tubes were placed in a 37°C oven. After ~24
h tubes were removed from the oven and sonicated (with scaffolds still in reacted SBFx5
Solution A) for ~ 10 sec to remove loosely bound CaP. Each scaffold was then placed in a 96well plate and rinsed 3x with MilliQ water.
Each scaffold was then placed in a 1.5 ml centrifuge tube (EMD Millipore, Billerica,
MA) with a 0.65 μm filter-membrane. The micro-centrifuge tubes are made up of two
compartments separated by the membrane; this allows the sample to sit submerged in solution on
top of the membrane until tubes are centrifuged, which then forces the solution through the
scaffold and through the membrane, leaving the supernatant separated from the sample. 300 μl of
1 mg/ml poly-L-Glutamic acid (PLGlut, Sigma, St. Louis, MO) in saline was added to each tube
and allowed to adsorb to the scaffold for 10 min. Note that the membrane is of sufficiently fine
porosity that it does not allow the solution to go through it until the centrifugation step therefore
the scaffold is completely immersed in the solution. After 10 min, tubes were centrifuged for
~10 sec at 1000 rpms and the supernatants contained below the membrane were discarded. Each
scaffold was then rinsed 3x with saline with centrifugation after each rinse. Then 300 μl of 1
mg/ml poly-L-Lysine (PLLys, Sigma, St. Louis, MO) in saline was added to each tube and
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allowed to adsorb for 10 min, then centrifuged and rinsed 3x with saline. This procedure was
repeated until 8 bilayers of PEM were adsorbed (1 bilayer = PLGlut-PLLys).
After PEM8 application, recombinant human fibroblast growth factor 2 (FGF-2, R & D
Systems, Minneapolis, MN) was adsorbed by adding 2 μl of various FGF-2 working stocks
(prepared in saline) to each scaffold and allowed to bind for 1 h at room temperature. The
following doses were tested: 0, 0.25, 5, 100, and 125 ng FGF-2. After FGF-2 adsorption, the
scaffolds were rinsed 3x in saline then put in 300 μl DMEM high glucose, pyruvate medium,
(No. 11995, Gibco BRL, Invitrogen) and stored in a 8-20°C refrigerator until ready for
implantation. Prior to implantation the scaffolds were centrifuged for ~ 10 sec at 1000 rpms.
This entire procedure is illustrated in Fig. 4.2.
4.2.2.b Preparation of bCaP-PEM30 coated Healos®
Healos® scaffolds were cut and sterilized as previously described. A 2 μg dose of recombinant
human bone morphogenic protein 2 (BMP-2, R & D Systems, Minneapolis, MN) was applied to
the Healos® scaffolds by adding 2 μl of 1 mg/ml stock made in PBS to each scaffold and
allowing it to adsorbed for 1 h at room temperature.
For bCaP application, the two-step SBF method described in Ch. 2 was used to produce a
nanocrystalline bCaP layer rather than just the amorphous layer previously described. During
BMP-2 adsorption SBF Solution A was prepared as described in Ch. 2. Scaffolds were added to
the beaker equipped with a stir bar. The beaker was covered with saran wrap with 20-30 holes
punched into it and placed on a stir plate set to match the mixing during Solution A prep (~ 130
rpms) in a 37°C oven. After ~24 h the beaker was removed from the oven and sonicated (with
scaffolds still in reacted Solution A) for ~ 10 sec. Prior to immersion in Solution B, the scaffolds
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were gradually dehydrated by being passed through a graded series of increasing concentrations
of ethyl alcohol.
Solution B was prepared as described in Ch. 2. Scaffolds were added to the beaker
equipped with a stir bar. The beaker was covered with saran wrap with 20-30 holes punched into
it and placed on a stir plate set to match the mixing during Solution B prep (~ 130 rpms) in a
50°C oven. After 7 or 24 h, the beaker was removed from the oven and sonicated (with scaffolds
still in reacted Solution B) for ~ 10 sec. The scaffolds were gradually dehydrated by being
passed through a graded series of increasing concentrations of ethyl alcohol.
After bCaP deposition, each scaffold was then placed in a 0.65 μm micro-centrifuge tube
and 30 bilayers of PLGlut-PLLys were applied as previously described for PEM8. After PEM30
application, a 5 ng recombinant human fibroblast growth factor 2 (FGF-2, R & D Systems,
Minneapolis, MN) dose was adsorbed and allowed to bind for 1 h at room temperature. After
FGF-2 adsorption, the scaffolds were rinsed 3x in saline then put in 300 μl DMEM high glucose,
pyruvate medium, (No. 11995, Gibco BRL, Invitrogen) and stored in a 8-20°C refrigerator until
ready for implantation. Prior to implantation the scaffolds were centrifuged for ~ 10 sec at 1000
rpms. This entire procedure is illustrated in Fig. 4.3.
4.2.3 Characterization
4.2.3.a Scanning Electron Microscopy (SEM)
The microscopic morphology of the coated scaffolds was characterized using SEM (JSM 5900LV, Jeol USA Inc. Peabody, MA). Coated scaffolds were also cut in half, allowing
examination of the innermost fibers of the Healos® scaffold via SEM.
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4.2.4 In Vivo Osteogenesis Assays with a Mouse Calvarial Defect Model
The CD1 female mice were purchased from Jackson Laboratory, (Bar Harbor, ME) and used for
studies at 4-7 months of age. Col 3.6-cyan female reporter mice (with a CD1 background) were
bred in house and used for studies at 4-7 months of age. Mice in this age range were used
because they are considered skeletally mature. All animal experimental procedures were
approved by the Animal Care and Use Committee of the University of Connecticut Health
Center, (Farmington, CT).
Mice were anesthetized and placed in a prone position, and the cranium was shaved of
fur, washed with betadine, and swabbed with alcohol. The periosteum was incised over the
parietal bone in the frontal plane with a scalpel blade. A 3.5 mm diameter hole was created in the
center and through one of the two parietal bones using a trephine and avoiding cranial sutures. A
prepared scaffold was implanted in the calvarial defect, and then the periosteum and
subcutaneous tissue was closed with sutures, followed by closing sutures of the skin incision.
The animals were allowed to recover until ambulating and feeding normally. Mice were
euthanized by asphyxiation with carbon dioxide, and calvaria were harvested after 1, 3, or 4
weeks post-surgery. Mice being sacrificed after 1 week were used to evaluate proliferating cells;
therefore all mice in these groups received peritoneal cavity injections of 3 μg/g EdU (5-ethynyl2-deoxyuridine, a nucleoside analog of thymidine) 1 day prior to euthanasia.

New bone

formation at 3 and 4 weeks was evaluated with x-ray and microCT analysis. 1-6 mice/group
were used for the calvarial defect studies; specific “n” for each group/study will be indicated in
results figures.

102

Emily Elizabeth Jacobs – University of Connecticut, 2016

4.2.5 Statistical Analyses
Statistical significances were determined by unpaired t-tests and one-way ANOVA with Tukey
post-tests, with a p-value < 0.05 being considered statistically significant. Standard deviations
are shown in all figures.
4.3 Results
4.3.1 Characterization of CaP, bCaP, and bCaP-PEM coated Healos®
Amorphous CaP could successfully be deposited on Healos® as evident by SEM (Fig. 4.4), and
had similar morphology to when amorphous CaP was applied to the sand blasted disks for in
vitro studies (Fig. 2.3B). bCaP prepared by either 7 h or 24 in Solution B could be deposited on
Healos®, however, observed porosity decreased with increasing time in Solution B (Fig. 4.5).
bCaP(7) prepared by 7 h in Solution B, on the outer/surface fibers of the Healos® scaffold had
the same nanocrystalline morphology (Fig. 4.6C) to bCaP deposited on the sandblasted disks for
in vitro studies (Fig. 2.3C). These nanocrystals were still evident on the innermost fibers of the
Healos® scaffold however they were less densely packed (Fig. 4.6C top vs. bottom panel).
Uniform deposition of bCaP(7) on outer and inner Healos® fibers was achieved. After PEM30
application to Healos-bCaP(7), the nanocrystals of bCaP(7) layer can no longer be observed (Fig.
4.7). Similar, uniform morphology was observed for the outer and inner fibers of the Healos®
scaffold (Fig. 4.7 top vs. bottom panel).
4.3.2 In Vivo Osteogenesis Assays with a Mouse Calvarial Defect Model
4.3.2a Determining a Sub-optimal Dose of BMP-2 for CaP-PEM8 Delivery
0.5 μg BMP-2 delivered from Healos® scaffolds coated with amorphous CaP and 8 bilayers of
PEM (BMP2-CaP-PEM8) resulted in minimal new bone formation as compared to the BMP-2-
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free control scaffolds after 4-weeks post-surgery (Fig. 4.8). The new bone formation was only
evident on the edges of the defect (Fig. 4.8 red circles). This was considered a desirable result
because this dose of BMP-2 did not completely heal the defect after 4-weeks implantation; it was
selected to be used as the control dose of BMP-2 that FGF-2 was used in combination with to
enhance BMP-2-stimulated in vivo bone formation in future studies.
4.3.2b Proliferative Effects of the Dual Delivery of FGF-2 and BMP-2 from CaP-PEM8
The addition of 25 ng FGF-2 to scaffolds coated with BMP2-CaP-PEM8 increased the number of
EdU positive host cells, therefore proliferating cells, present at the center of the calvarial defect
1-week after implantation as compared to the BMP-2 only control (Fig. 4.9A, B). The addition of
125 ng FGF-2 to scaffolds coated with BMP2-CaP-PEM8 significantly increased the number of
EdU positive host cells, therefore proliferating cells, present at the center of the calvarial defect
1-week after implantation as compared to the BMP-2 only control and BMP2-CaP-PEM8-FGF2
(25 ng) (Fig. 4.9C, * p < 0.05, ** p < 0.01).
4.3.2b Osteogenic Effects of the Dual Delivery of FGF-2 and BMP-2 from CaP-PEM8
Though it was observed that the 125 ng dose of FGF-2 delivered with 0.5 μg BMP-2 (HealosBMP2-CaP-PEM8-FGF2) significantly increased the number of proliferating cells within the
center of the defect after 1-week implantation, this dose of FGF-2 had an inhibitory effect on
new bone formation (Fig. 4.10A-D).

After 4-weeks implantation, the FGF-2 and BMP-2

scaffolds (Healos-BMP2-CaP-PEM8-FGF2) resulted in 0.73 + 0.12 mm3 bone volume,
compared to the BMP-2 only scaffolds (Healos-BMP2-CaP-PEM8) that resulted in 1.83 + 1.13
mm3 bone volume (Fig. 4.10E).
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These results prompted additional testing of Healos® coated with BMP2-CaP-PEM8FGF2 using the 0.5 μg dose of BMP-2, plus 0.25, 5, and 100 ng FGF-2. After 4-weeks
implantation the BMP-2 only group resulted in 1.83 + 1.13 mm3 bone volume, and the FGF-2
doses resulted in 0.17 + 0.17 (0.25 ng), 0.23 + 0.24 (5ng), and 0.35 + 0.24 (100 ng) mm3 bone
volume. All doses of FGF-2 tested resulted in significant decrease in new bone
formation/volume compared to the BMP-2 only control (Fig. 4.11, * p < 0.05, ** p < 0.01).
4.3.2b Osteogenic Effects of the Sequential Delivery of FGF-2 and BMP-2 from bCaP-PEM30
Healos® coated with nanocrystalline bCaP and 30 bilayers of PEM, and no growth factors,
(bCaP-PEM30) resulted in minimal to no bone formation after 3-weeks post- calvarial defect
surgery (0.38 mm3, Fig. 4.12A). Healos® coated with BMP2-bCaP-PEM30 (BMP-2 = 2 μg)
resulted in new bone formation only observed around the defect edges (0.89 + 0.32 mm3, Fig.
4.12B, red circles). Healos® coated with BMP2-bCaP-PEM30-FGF2 (BMP-2 = 2 μg, FGF-2 = 5
ng) resulted in new bone formation observed around the defect edges and some within the center
of the defect (1.32 + 0.33 mm3, Fig. 4.12C, red circles). The addition of BMP-2 and FGF-2
delivered from bCaP-PEM30 resulted in a trend of increasing bone volume as compared to the
control scaffold with no growth factor and the BMP-2 only scaffold, however these results were
not statistically significant (Fig. 4.12D). It should be noted that the BMP-2 only, and BMP-2 and
FGF-2 groups could not be statistically compared to the growth factor-free control group because
this group had a n = 1.
4.4 Discussion
Growth factors have different effects on natural bone regeneration depending on the
developmental stage of the healing process they are present during. Specifically, the sequential
delivery of FGF-2, then BMP-2 has been shown to increase in vitro osteogenesis over co-
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delivery of both factors [88, 90]; therefore, there is a need for new biomaterials to
biomimetically deliver multiple growth factors in a sequential manner to maximize their
stimulatory effects. This chapter focused on the use of the novel, sequential delivery bCaP-PEM
coating applied to a commercially available bone graft substitute, to deliver FGF-2 and BMP-2
to enhance in vivo osteogenesis in a mouse calvarial defect model over BMP-2 only delivery.
Both BMP-2 and FGF-2 have been successfully delivered individually from calcium
phosphate/hydroxyapatite materials [195-201], and PEM films and particles [156, 160, 163, 202205]. The combination of CaP and PEM without growth factors has been shown to stimulate
osteogenesis due to CaP’s biomimetic, osteoconductive properties [120, 123, 157, 180].
Furthermore, the combination of CaP and PEM has also been demonstrated to successfully
deliver BMP-2 [116, 117]. Due to the synergistic properties of FGF-2 and BMP-2 used in
combination on osteogenesis, it seemed logical to deliver both growth factors from a calcium
phosphate/polyelectrolyte biomaterial to stimulate in vivo osteogenesis.
Amorphous CaP could be uniformly applied to the fibers of the Healos® scaffold (Fig.
4.4). Using the amorphous CaP coating with 8 bilayers of PEM (CaP-PEM8), calvarial defect
studies were conducted in 4-7 month old female mice to determine first, a suboptimal dose of
BMP-2, and then to study the proliferative and osteogenic effects of the addition of FGF-2
delivered with the BMP-2. In all studies the BMP-2 was adsorbed directly to the Healos®
scaffold, then embedded under CaP-PEM8. In the groups with FGF-2, FGF-2 was adsorbed as
the outermost layer of the scaffold coating (Healos-BMP2-CaP-PEM8-FGF2).
In the first study, 0.5 μg BMP-2 delivered from CaP-PEM8 coated Healos® scaffold
resulted in minimal bone formation only evident along the edges of the defect after 4-weeks
implantation (Fig. 4.8, red circles). This was considered a desirable result at the time; the goal of
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this study was to determine a suboptimal dose of BMP-2 that could not completely heal the
defect in the 4-week time point because it was hypothesized that the addition of FGF-2 to low
dose BMP-2 could enhance in vivo osteogenesis; it was first necessary to determine a dose of
BMP-2 that could be enhanced (because it could not heal the defect alone), and this was
achieved with the 0.5 μg dose. With continued testing of the BMP-2 only group as the control for
the FGF-2 dosing experiments, it was determined that the 0.5 μg dose was too suboptimal; with
or without FGF-2 delivered from the CaP-PEM8 coating, minimal if any bone formation was
observed after 4-weeks implantation. The lack of observed defect healing is why the dose of
BMP-2 was increased to 2 μg for continued testing with the bCaP-PEM30 coating, in addition to
the fact that the bCaP layer is much thicker than the amorphous CaP layer; this dose had
demonstrated better in vivo efficacy for stimulating bone formation in a similar mouse calvarial
defect model, [84, 108].
The reason FGF-2 was selected to be used in combination with BMP-2 was because it
was hypothesized that the FGF-2 would stimulate the migration and proliferation of
osteoprogenitor cells into the calvarial defect, therefore providing more cells within the defect to
be differentiated and result in better overall healing. The next animal study looked at the
proliferative effects of adding FGF-2 to the BMP2-CaP-PEM8 coated scaffold after just 1-week
implantation. The addition of FGF-2 resulted in an observed increase in DAPI+ cells and
increased EdU+ cells at the center of the defect as compared to the BMP-2 only group (Fig. 4.9).
This indicated that not only were there more cells present at the center of the defect with
increasing FGF-2, but these cells were also actively proliferating. These results confirmed the
first part of the hypothesis and are supported by the literature [36, 78].
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The second part of the hypothesis was that the increase in number of cells present at the
center of the defect after 1-week would lead to overall increased bone formation after 4-weeks
implantation. When looking at total bone volume after 4-weeks implantation, the 0.5 μg BMP-2
only group again resulted in minimal bone formation, only along the edges of the defect
(Fig.4.10C, red circles). The addition of FGF-2 (125 ng) to the BMP-2 resulted in less bone
formation as evident by microCT (Fig. 4.10D, red circle), and a decrease in quantified bone
volume, as compared to the BMP-2 only group (Fig. 4.10E).

These results indicate that even

though the 125 ng FGF-2 was stimulating the proliferation of osteoprogenitors within the defect
after 1-week, the dose had an overall inhibitory effect on new bone formation after 4-weeks. It is
known that too much and/or late stage exposure of FGF-2 can inhibit in vitro and in vivo bone
formation when delivered with BMP-2 because it can maintain cells in an undifferentiated state
[90, 93, 194]. This led to the assumption that 125 ng FGF-2 was too high of a dose, and
prompted additional testing with FGF-2 doses of 0.25, 5, and 100 ng in combination with the 0.5
μg BMP-2 (Healos-BMP2-CaP-PEM8-FGF2). All doses of FGF-2 tested significantly inhibited
bone formation as compared to the BMP-2 only group (Fig. 4.11).
This led to the hypothesis that delivery of FGF-2 and BMP-2 from the CaP-PEM8
coating was occurring as co-delivery and not as the intended sequential delivery. These animal
studies were conducted concurrently with the in vitro studies reported in Ch. 2 and 3. To recall,
the in vitro diffusion studies described in section 2.2.3.b determined that the CaP-PEM8 coating
significantly improved interlayer diffusion of embedded antimycin A (AntiA) as compared to a
PEM8 only coating, however, 42% of the cells still accessed at least some of the AntiA within
the first 24 h resulting in their death (Fig 2.7A). The conclusion made from this section was “the
CaP-PEM8 coating would be insufficient for sequential delivery because the embedded ‘Factor
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2’ can still be accessed immediately”. In the present animal studies, it is most likely that the
FGF-2 and BMP-2 are being delivered together from the CaP-PEM8 coating as a co-delivery
system. As previously mentioned, it was also decided that the suboptimal dose of BMP-2
needed to be increased to 2 μg for continued testing.
Co-delivery of FGF-2 and BMP-2 from PEG hydrogels [84] or colloidal gelatin gels
[102] can have inhibitory effects on in vivo bone formation when compared to BMP-2 alone.
Some co-delivery systems such as collagen sponges have even shown that the combination of
FGF-2 and BMP-2 was not only inhibitory compared to the BMP-2 only group, but was also
inhibitory compared to the growth factor-free control [100]. Similar results were observed when
the FGF-2 and BMP-2 were administered as bolus injections in a rat mandible defect; the codelivery of factors was significantly worse at inducing bone apposition compared to BMP-2
alone, and was comparable to the control that was not treated with any growth factors [95].
Publications reporting co-delivery of FGF-2 and BMP-2 appear to have conflicting
results both in vitro and in vivo because dose or dose ratio is not always considered. There are
publications where the co-delivery of FGF-2 and BMP-2 enhanced in vitro and in vivo
osteogenesis over single factor delivery and/or spiking [87, 92, 94, 97, 98, 206]; in these studies
ng quantities of FGF-2 were used and were relatively low compared to the dose of BMP-2 used
(usually μgs). Both Kuhn et al. and Wang et al. investigated the combined delivery of FGF-2 and
BMP-2 and provide summaries of the contradictory results [88, 102]. In general, they observed
that low doses of FGF-2 in combinations with BMP-2 were stimulatory (ng quantities), whereas
high doses of FGF-2 with BMP-2 were inhibitory (μg quantities). The ratio of FGF-2 to BMP-2
is also important to consider, where doses of FGF-2 greater than BMP-2 tend to be inhibitory.
Nakamura et al. hypothesizes that this phenomenon may be the result of high dose fibroblast
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growth factor stimulating inhibitors of BMP-2 signaling (Smad 6) or stimulating
osteoclastogenesis that leads to decreased bone formation or bone density [93]. The release
kinetics from the delivery system may also influence the stimulatory or inhibitory effects of codelivery of FGF-2 and BMP-2. As previously mentioned, FGF-2 promotes the mitogenic activity
of osteoprogenitors, therefore rapid release of FGF-2 early on in bone healing may reduce the
osteogenic potential of these cells leading to reduced bone formation.
Contrary to published co-delivery results, sequential delivery of FGF-2 and BMP-2 has
lead to more consistent stimulatory effects. This is most likely due to the fact that growth factors
in general, are very stage-specific during the bone healing process. The sequential delivery of
first FGF-2, then BMP-2 when spiked into cell cultures results in enhanced in vitro osteogenesis
over co- or single factor delivery [85, 88, 90, 91]. The challenge arises from developing a truly
sequential delivery system. Many materials claim to be “sequential” when in reality they only
provide the prevention of burst release of the factor they want delivered second; if you check the
release profiles one will observe that both factors are being released simultaneously, they are just
releasing at different rates [102, 107, 131, 156, 207, 208]. When release of FGF-2 and BMP-2
from a material is truly sequential, a stimulatory effect on osteogenesis is usually observed. Lei
et al. developed core-shell microspheres where FGF-2 and BMP-2 were encapsulated in either
the core or the shell. They demonstrated that the in vitro sequential delivery of first FGF-2 from
the shell, and then BMP-2 from the core induced osteogenic differentiation of human
mesenchymal stem cells better than the growth factors delivered in parallel [89]. Sequential
delivery of BMP-2 first, then FGF-2 was inhibitory, again demonstrating that not only is
sequential delivery important, but sequential delivery that mimics the natural biological process
is key to enhancing osteogenesis.
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In the present study, a stimulatory effect from the delivery of FGF-2 and BMP-2 on in
vivo osteogenesis was observed when the growth factors were delivered from the bCaP-PEM30
coating (Fig. 4.12), proven to provide sequential delivery in vitro (Fig. 3.3) and higher doses of
FGF-2 (5ng) and BMP-2 (2 μg) were used. Though these results were not statistically significant,
continued studies focused on optimizing the relative dosing of FGF-2 to BMP-2, as well as
continued work on tuning the in vivo delivery kinetics of the growth factors from the coating
could lead to the bCaP-PEM coating being ideally suited as a sequential, multifactor delivery
system capable of being applied to various scaffolds and/or implants for enhanced bone
regeneration.
4.5 Conclusions
Both the novel dual delivery CaP-PEM8 coating, and the novel sequential delivery bCaP-PEM30
coating could be uniformly applied to the three-dimensional bone graft substitute, Healos®. Codelivery of FGF-2 and BMP-2 from CaP-PEM8 coatings resulted in inhibited in vivo bone
formation in a calvarial defect model, compared to the BMP-2 only coating. However, sequential
delivery of FGF-2 then BMP-2, from bCaP-PEM30 coatings resulted in an observed trend of
increased in vivo bone formation in a calvarial defect model, compared to the BMP-2 only
coating. These results suggest the potential for bCaP-PEM30 coating applied to a 3-D implant to
be used for sequential delivery of multiple growth factors to enhance in vivo bone formation.
Regardless of the delivery system, these results and others previously published, stress the
importance of dosing, dose ratio of two different factors, timing, and order of growth factor
delivery used to enhance in vivo bone regeneration. Increased doses of BMP-2 with low dose
FGF-2 should be further investigated.
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Figure 4.1 Schematic representation of BMP-2 only (A), and BMP-2 and FGF-2 (B) delivery
from Healos-bCaP-PEM. The theoretical single- (C), and sequential- (D) delivery profiles from
Healos-bCaP-PEM.
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Figure 4.2 Schematic representation of the Healos-BMP2-CaP-PEM8-FGF2 procedure made
with only amorphous calcium phosphate (CaP) with no mixing, and 8 bilayers of PEM.
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Figure 4.3 Schematic representation of the Healos-BMP2-bCaP-PEM30-FGF2 procedure made
with biomimetic, nanocrystalline, calcium phosphate (bCaP) with mixing, and 30 bilayers of
PEM.
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Figure 4.4 Low magnification SEM images of Healos® (A) and Healos® coated with
amorphous CaP (B), (scale bar = 50 μm). High magnification SEM image of Healos® coated
with amorphous CaP (C), (scale bar = 10 μm).
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Figure 4.5 SEM images of Healos® (A), Healos® coated with nanocrystallline bCaP(7) made
by 7 h in Solution B (B), and nanocrystalline bCaP(24) made by 24 h in Solution B (C), (scale
bar = 500 μm).
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Figure 4.6 Low magnification SEM images of the outer and inner fibers of Healos® (A) and
Healos® coated with nanocrystalline bCaP(7) (B), (scale bar = 10 μm). High magnification SEM
image of the outer and inner fibers of Healos® coated with nanocrystalline bCaP(7) (C), (scale
bar = 1 μm).
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Figure 4.7 SEM images of the outer (A) and inner fibers (B) of Healos® coated with
nanocrystalline bCaP(7) and 30 bilayers of PEM.
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Figure 4.8 4-week post-surgery x-rays (A, B), microCT 3-D reconstructions (C, D), and
microCT cross-sections (E, F) of calvaria implanted with Healos® coated with CaP-PEM8 (top
panel) and BMP2-CaP-PEM8 (bottom panel). BMP-2 dose = 0.5 μg. New bone formation is
circled in red.
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Figure 4.9 Schematic representation of where within the defect FGF-2 effects are being
observed and quantified 1-week post-surgery (A). Fluorescent images of DAPI and EdU stained
cells showing increase in staining with the addition of 25 and 125 ng FGF-2 as compared to
BMP-2 alone (B). Quantified results showing 125 ng FGF-2 dose significantly increases number
of EdU+ cells on day 7 as compared to BMP-2 alone and 25 ng FGF-2 dose (C). (* p < 0.05, **
p < 0.01). (Healos® was coated with BMP2-CaP-PEM8 + FGF2).
ANOVA P value = 0.0029
Tukey's multiple comparisons test

Mean
Diff.

95% CI of
diff.

Significa Summ
nt?
ary

BMP-2 (0.5ug) vs. BMP-2 (0.5ug) + FGF-2
(125ng)

-198.1

-313.1 to 83.17

Yes

**

BMP-2 (0.5ug) + FGF-2 (25ng) vs. BMP-2 (0.5ug)
+ FGF-2 (125ng)

-130.3

-245.2 to 15.30

Yes

*
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Figure 4.10 4-week post-surgery microCT 3-D reconstructions (A, B), and microCT crosssections (C, D), of calvaria implanted with Healos® coated with BMP2-CaP-PEM8 (top panel)
and BMP2-CaP-PEM8-FGF2 (bottom panel). BMP-2 dose = 0.5 μg, FGF-2 dose = 125 ng. New
bone formation is circled in red and quantified in (E).
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Figure 4.11 4-week post-surgery microCT 3-D reconstructions (top panel) and microCT crosssections (bottom panel) of calvaria implanted with Healos® coated with BMP2-CaP-PEM8 (A),
and BMP2-CaP-PEM8-FGF2 with an FGF-2 dose = 0.25 ng (B), 5 ng (C), and 100 ng (D).
BMP-2 dose = 0.5 μg. New bone formation is circled in red and quantified in (E). (* p < 0.05, **
p < 0.01).
ANOVA P value = 0.0027
Tukey's multiple comparisons test

Mean
Diff.

95% CI of Significan
diff.
t?

Summar
y

0.5 ug BMP-2 vs. 0.5 ug BMP-2 + 0.25 ng 1.662
FGF-2

0.6170
2.707

to Yes

**

0.5 ug BMP-2 vs. 0.5 ug BMP-2 + 5 ng 1.602
FGF-2

0.4733
2.731

to Yes

**

0.5 ug BMP-2 vs. 0.5 ug BMP-2 + 100 ng 1.482
FGF-2

0.2753
2.689

to Yes

*
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Figure 4.12 3-week post-surgery microCT 3-D reconstructions (top panel) and microCT crosssections (bottom panel) of calvaria implanted with Healos® coated with bCaP(7)-PEM30 (A),
BMP2-bCaP(7)-PEM8 (B), and BMP2-bCaP(7)-PEM8-FGF2 (C). BMP-2 dose = 2 μg, FGF-2
dose = 5 ng. New bone formation is circled in red and quantified in (D).
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Chapter 5
Suggested Future Directions and Conclusions
The goal of these studies was to develop a biomaterial capable of sequential delivery of multiple,
biologically active factors to better stimulate tissue repair that involves a complicated cascade of
factors in order to regenerate tissue. More specifically, the hope was to develop a coating process
that could sequentially deliver low dose FGF-2 and BMP-2 with a staggered release of at least
several days that could be applied to a commercially available bone graft substitute to enhance in
vivo osteogenesis, with the long-term goal being to overcome clinical complications with high
dose BMP-2. This work focused on the incorporation of a biomimetic calcium phosphate (bCaP)
layer into a poly-L-lysine/poly-L-glutamic acid PEM design to prevent interlayer diffusion of
growth factors resulting in a sequential, multifactor delivery system that could be applied to twodimensional (2-D) and three-dimensional (3-D) substrates. The work presented in this
dissertation proved the hypothesis: If the bCaP barrier layer could prevent diffusion of multiple
factors within a PEM coating, then sequential delivery of factors could be achieved from a
bCaP-PEM coated biomaterial.
During this thesis research a variety of methods were used to modify the MC3T3-E1mediated delivery kinetics from PEM coatings and are summarized in Table 5.1. It was shown
that the unmodified poly-L-Lysine/poly-L-Glutamic acid PEM only coating resulted in interlayer
diffusion and immediate access to an embedded factor (Fig. 2.7A, 2.9B), proving that a PEM
only system could not provide sequential delivery of multiple factors. The addition of amorphous
CaP to PEM prevented some interlayer diffusion of embedded antimycin A (AntiA), however
significant access to the AntiA had occurred by 24 h (Fig. 2.7-2.8), suggesting it would also be
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incapable of sequential delivery over the 3+ day time frame that was the goal of this research.
The addition of nanocrystalline bCaP to PEM (bCaP-PEM30) successfully prevented interlayer
diffusion of embedded AntiA and provided delayed access to the embedded factor beyond 24 h
(Fig. 2.9).
An alternative approach to preventing interlayer diffusion within a PEM coating would
be to use hydrophobic polyelectrolytes that result in linear growth with the layer-by-layer (LBL)
application. Hydrophilic poly-L-Lysine (PLLys) and poly-L-Glutamic acid (PLGlut) were
selected for use because it was known that these polyelectrolytes degraded via cell-mediated
enzymatic action on the film itself [150], providing localized delivery and a system that does not
rely on diffusion. Diffusion based systems were avoided because not only are they more difficult
to control release from, but those system require excessive dosing of growth factor to provide the
therapeutic concentration to the local tissue. A cell-mediated delivery system would allow us to
use low concentrations of growth factor making the biomaterial safer and avoiding the off-target,
unwanted side effects that are associated with clinical, supraphysiologic dosing [19, 27, 30]. The
problem with PLLys and PLGlut is that they are hydrophilic, which means that during the LBL
build up of the film, the polyelectrolytes are constantly rearranging causing an incorporated
growth factor within the film to also constantly rearrange and resulting is a blended structure
lacking any ability for sequential delivery. In the present studies, it was decided to incorporate a
biomimetic calcium phosphate layer into the PEM system to prevent the interlayer diffusion of
one of the growth factors and effectively provide sequential delivery. An alternative that is
worth further investigation would be to use hydrophobic polyelectrolytes such as hyluronan
(HA) and/or dextran sulfate (DS) that result in non-diffusing systems [146, 154]. Both of these
polyelectrolytes result in linear growth. Interlayer diffusion does not occur in these systems,
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which, as a result, form spatially organized structures wherein factors incorporated at a given
step are able to interact only with neighboring factors that are in close proximity (two to three
layers) [209]. The disadvantage to using HA and/or DS is that rather than being cell-mediated,
their degradation is hydrolytic, meaning release of growth factors depends on the water content
in the area; this could lead to diffusion of factors away from the target tissue. However, these
polyelectrolytes can form compartmentalized films to potentially provide sequential delivery
without the need for covalent cross-linking (which would inactivate the growth factor) or a
barrier layer. Their use, with low doses of growth factor (minimizing the potential for diffusion),
is a viable option for future work.
A combination of a cytotoxic compound (AntiA) and a proliferation compound (FGF-2)
was found to be the ideal combination to study the multifactor, cell-mediated delivery kinetics of
the bCaP-PEM coating. With the cytotoxic AntiA embedded beneath the coating it was easy to
judge when the cells had significantly attained access to the second factor. Using this method we
were able to show that bCaP-PEM coating was capable of local, cell-mediated delivery and did
not release adsorbed factors through diffusion at the concentrations used in the present study.
The bCaP-PEM30 coating was able to provide sequential delivery of first FGF-2 and then an
embedded AntiA, delaying access to the AntiA for up to 3 days when cultured with
osteoprogenitor cells (Fig. 3.3). Increasing the number of PEM bilayers (30 to 102) within the
coating (Fig. 3.4), or changing the chemical composition of the polyelectrolytes (L- to Denantiomers, Fig. 3.5) could not further delay osteoprogenitor access to the embedded AntiA but
could potentially inhibit/delay delivery of the FGF-2. . Increasing (~24 μm) the thickness of the
bCaP coating from the normal ~6 μm did not change the initial timing of access to the embedded
AntiA, but did change the delivery of AntiA from burst to sustained delivery over the course of 4
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days to the osteoprogenitor cells (Fig. 3.8-3.10). Changing the cell type used to evaluate delivery
kinetics from the coating from osteoprogenitors to macrophages significantly increased access
time to the embedded factor (Fig. 3.11-3.14). When the macrophages were seeded at a low
density (7.9k cells/cm2) the bCaP-PEM30 coating provided 3 days delayed access to the
embedded factor (Fig. 3.12), similar to the osteoprogenitor cells. When the macrophages were
seeded at a high density (30k cells/cm2) the bCaP-PEM30 coating failed to provide any delayed
access to the embedded factor (Fig. 3.13). These results highlight the importance of cell type
and number when evaluating delivery kinetics from a cell-mediated delivery system.
Considering the variable delivery kinetics of the embedded AntiA from the bCaP-PEM
coating in vitro, via changing the cell type used in the study, it is critical to better understand the
mechanism of action various cell types that will interact with the bCaP-PEM coating in vivo, use
to degrade the coating and access the embedded factor. Considering the increased in vitro
delivery kinetics of the embedded AntiA from the bCaP-PEM coating that occurred when
changing the cell type from pre-osteoblasts to monocyte/macrophages, it is difficult to predict the
in vivo response from the in vitro studies. To better predict the in vivo response it is critical to
better understand the mechanism of degradation of the various cell types that will interact with
the bCaP-PEM coating in vivo. Continued in vitro cell assays should be performed using
different cell types (macrophages, osteoprogenitors, osteoclasts, osteoblasts, etc.) as well as
different seeding densities or mixtures of the cell types. Evaluation of the bCaP-PEM coating via
scanning electron microscopy (SEM), after cell culture, should be performed to observe extent of
coating degradation.
Both the novel dual delivery CaP-PEM8 coating, and the novel sequential delivery bCaPPEM30 coating could be uniformly applied to the three-dimensional bone graft substitute,
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Healos® (Fig. 4.4-4.7). Co-delivery of FGF-2 (0.25, 5, 100, 125 ng) and BMP-2 (0.5 μg) from
CaP-PEM8 coatings resulted in inhibited in vivo bone formation in a calvarial defect model,
compared to the BMP-2 only coating (Fig. 4.10-4.11).

Considering these results, it was

determined that the 0.5 μg BMP-2 dose was too low. However, sequential delivery of FGF-2 (5
ng) then BMP-2 (2 μg), from bCaP-PEM30 coatings resulted in an observed trend of increased in
vivo bone formation in a calvarial defect model, compared to the BMP-2 only coating (Fig.
4.12). Further studies with a larger number of animals may increase this effect. Increasing the
dose of BMP-2 is also necessary in order to see a benefit from combined FGF-2 delivery. These
results and others previously published, stress the importance of dosing, ratio of doses, timing,
and order of growth factor delivery used to enhance in vivo bone regeneration. Further studies
need to be conducted to optimize the dosing of FGF-2 and BMP-2 to lead to robust, new bone
formation in vivo that cannot be achieved by BMP-2 alone.
In summary, the work presented in this dissertation resulted in the development of novel
biomimetic calcium phosphate/polyelectrolyte coating capable of cell-mediated, sequential,
multifactor delivery, providing three-day delayed access of an embedded factor to
osteoprogenitor and macrophage cells. This technology has the versatility to be applied to 2-D or
3-D substrates and can be utilized in multiple research applications where a sequential delivery
profile activated by cell degradation of matrix is desired. The results suggest the biomimetic
calcium phosphate/polyelectrolyte coating applied to a 3-D implant could be an ideal system for
sequential delivery of multiple growth factors to enhance in vivo bone formation.

128

Emily Elizabeth Jacobs – University of Connecticut, 2016

Table 5.1 Summary of cellular access timing to embedded AntiA (213 μg/disk) when cultured
on the various coatings reported in this thesis. (FGF-2 Dose = 150 ng).
AntiA Embedded

Cell Type

Seeding Density

Access Time

(cells/cm2)

Beneath
PEM8

MC3T3-E1

10k

< 24 h

CaP-PEM8

MC3T3-E1

10k

< 24 h

CaP-PEM30

MC3T3-E1

10k

< 24 h

PEM30

MC3T3-E1

40k

< 24 h

bCaP-PEM30

MC3T3-E1

40k

3 days

bCaP-PEM30-FGF2

MC3T3-E1

40k

3 days, burst delivery

bCaP-PEM102-FGF2

MC3T3-E1

40k

3 days

bCaP-PEMD30-FGF2

MC3T3-E1

40k

3 days

bCaP(7)-PEM30-FGF2

MC3T3-E1

40k

3 days

bCaP(48)-PEM30-FGF2

MC3T3-E1

40k

3 days/sustained delivery

bCaP-PEM30-FGF2

RAW 264.7

7.9k

3 days

bCaP-PEM30-FGF2

RAW 264.7

30k

<4h
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